0001645260 2021-01-01 2021-09-30 0001645260 2021-11-11 0001645260 2021-09-30 0001645260 2020-12-31 0001645260 TOMDF:ILSMember 2021-09-30 0001645260 TOMDF:ILSMember 2020-12-31 0001645260 2020-01-01 2020-09-30 0001645260 2021-07-01 2021-09-30 0001645260 2020-07-01 2020-09-30 0001645260 us-gaap:CommonStockMember 2019-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001645260 us-gaap:RetainedEarningsMember 2019-12-31 0001645260 2019-12-31 0001645260 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001645260 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001645260 2020-01-01 2020-03-31 0001645260 us-gaap:CommonStockMember 2020-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001645260 us-gaap:RetainedEarningsMember 2020-03-31 0001645260 2020-03-31 0001645260 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001645260 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001645260 2020-04-01 2020-06-30 0001645260 us-gaap:CommonStockMember 2020-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001645260 us-gaap:RetainedEarningsMember 2020-06-30 0001645260 2020-06-30 0001645260 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001645260 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001645260 us-gaap:CommonStockMember 2020-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001645260 us-gaap:RetainedEarningsMember 2020-09-30 0001645260 2020-09-30 0001645260 us-gaap:CommonStockMember 2020-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001645260 us-gaap:RetainedEarningsMember 2020-12-31 0001645260 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001645260 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001645260 2021-01-01 2021-03-31 0001645260 us-gaap:CommonStockMember 2021-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001645260 us-gaap:RetainedEarningsMember 2021-03-31 0001645260 2021-03-31 0001645260 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001645260 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001645260 2021-04-01 2021-06-30 0001645260 us-gaap:CommonStockMember 2021-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001645260 us-gaap:RetainedEarningsMember 2021-06-30 0001645260 2021-06-30 0001645260 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001645260 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001645260 us-gaap:CommonStockMember 2021-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001645260 us-gaap:RetainedEarningsMember 2021-09-30 0001645260 us-gaap:PreferredStockMember TOMDF:SharePurchaseAgreementMember TOMDF:ProvistaDiagnosticsIncMember 2021-04-17 2021-04-19 0001645260 TOMDF:OrdinaryStockMember TOMDF:SharePurchaseAgreementMember TOMDF:ProvistaDiagnosticsIncMember 2021-04-17 2021-04-19 0001645260 TOMDF:ProvistaDiagnosticsIncMember 2021-04-17 2021-04-19 0001645260 TOMDF:SharePurchaseAgreementMember TOMDF:ProvistaDiagnosticsIncMember 2021-04-17 2021-04-19 0001645260 2021-04-19 0001645260 TOMDF:TodosDepositSharesMember 2021-09-30 0001645260 TOMDF:TodosDepositSharesMember 2021-01-01 2021-09-30 0001645260 2021-07-01 2021-07-02 0001645260 2021-07-13 2021-07-15 0001645260 2021-07-02 0001645260 srt:MinimumMember 2021-07-02 0001645260 TOMDF:SharePurchaseAgreementMember 2021-01-01 2021-09-30 0001645260 2021-04-14 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember 2021-01-01 2021-09-30 0001645260 TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputRiskFreeInterestRateMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputExpectedTermMember TOMDF:MonteCarloSimulationModelMember 2021-04-14 2021-04-19 0001645260 TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputPriceVolatilityMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputSharePriceMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputConversionPriceMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:OptionalOrMaturityConversionMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:MandatoryConversionMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:MandatoryConversionMember TOMDF:MonteCarloSimulationModelMember 2021-04-14 2021-04-19 0001645260 TOMDF:MonteCarloSimulationsModelMember 2021-01-01 2021-09-30 0001645260 TOMDF:MandatoryConversionMember us-gaap:MeasurementInputRiskFreeInterestRateMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:MandatoryConversionMember us-gaap:MeasurementInputExpectedTermMember TOMDF:MonteCarloSimulationModelMember 2021-04-14 2021-04-19 0001645260 TOMDF:MandatoryConversionMember us-gaap:MeasurementInputPriceVolatilityMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:MandatoryConversionMember us-gaap:MeasurementInputSharePriceMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:MandatoryConversionMember us-gaap:MeasurementInputConversionPriceMember TOMDF:MonteCarloSimulationModelMember 2021-04-19 0001645260 TOMDF:OptionalOrMaturityConversionMember TOMDF:MonteCarloSimulationModelMember 2021-04-14 2021-04-19 0001645260 TOMDF:ThirdPartyMember 2021-09-30 0001645260 2020-01-01 2020-12-31 0001645260 TOMDF:BreakthroughDiagnosticsIncMember 2019-02-27 0001645260 TOMDF:BreakthroughDiagnosticsIncMember 2020-07-28 0001645260 2020-08-01 2020-08-31 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2020-12-30 2020-12-31 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2020-12-31 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-22 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-01 2021-01-22 0001645260 srt:MaximumMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-01 2021-01-22 0001645260 us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-22 0001645260 us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-01 2021-01-22 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-01 2021-09-30 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-07-01 2021-09-30 0001645260 TOMDF:AslanoPrivateLimitedMember 2021-09-30 0001645260 us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-01 2021-09-30 0001645260 TOMDF:LoanAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:LenderMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember 2021-04-28 2021-05-01 0001645260 TOMDF:LenderMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember 2021-05-01 0001645260 TOMDF:LenderMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:LenderMember TOMDF:NISMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember 2021-09-30 0001645260 TOMDF:PurchaserMember TOMDF:ClosingAgreementMember 2021-09-30 0001645260 TOMDF:PurchaserMember TOMDF:ClosingAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-08-27 2021-09-30 0001645260 TOMDF:ConvertibleBridgeLoanMember 2021-01-01 2021-09-30 0001645260 TOMDF:ConvertibleBridgeLoanMember 2021-07-01 2021-09-30 0001645260 TOMDF:AssignmentOfReceivableAgreementsMember 2021-01-01 2021-09-30 0001645260 TOMDF:FamilyOfficeInvestorMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-09 0001645260 TOMDF:FamilyOfficeInvestorMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-08 2021-04-09 0001645260 srt:MaximumMember TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-09 0001645260 TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-09 0001645260 TOMDF:PurchaserMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-04-09 0001645260 TOMDF:PurchaserMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-04-07 2021-04-09 0001645260 TOMDF:PurchaserMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-04-09 0001645260 TOMDF:FamilyOfficeInvestorMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-06 2021-04-09 0001645260 TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-06 2021-04-09 0001645260 2021-04-06 2021-04-09 0001645260 TOMDF:FamilyOfficeInvestorMember TOMDF:SecuritiesPurchaseAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:FamilyOfficeInvestorMember TOMDF:SecuritiesPurchaseAgreementMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-04-27 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-04-26 2021-04-27 0001645260 srt:MaximumMember us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-04-27 0001645260 us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-04-27 0001645260 TOMDF:YozmaGlobalGenomicFund1Member TOMDF:SecuritiesPurchaseAgreementMember 2021-04-26 2021-04-27 0001645260 TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-06 2021-04-09 0001645260 TOMDF:DetachableWarrantsMember 2021-04-27 0001645260 TOMDF:FinanaceExpensesMember 2021-01-01 2021-09-30 0001645260 TOMDF:FinanaceExpensesMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FirstAndSecondTranchesMember 2021-05-12 2021-05-13 0001645260 TOMDF:PromissoeryConvertibleNoteMember TOMDF:SecuritiesPurchaseAgreementMember 2021-07-07 0001645260 TOMDF:PromissoeryConvertibleNoteMember TOMDF:SecuritiesPurchaseAgreementMember 2021-07-06 2021-07-07 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-07-06 2021-07-07 0001645260 TOMDF:PromissoeryConvertibleNoteMember TOMDF:SecuritiesPurchaseAgreementMember 2021-09-23 0001645260 TOMDF:PromissoeryConvertibleNoteMember TOMDF:SecuritiesPurchaseAgreementMember 2021-09-22 2021-09-23 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-09-22 2021-09-23 0001645260 2021-07-19 0001645260 2021-07-18 2021-07-19 0001645260 TOMDF:RedeemablePreferredSharesMember 2021-07-26 0001645260 2021-07-26 0001645260 2021-07-25 2021-07-26 0001645260 us-gaap:InvestorMember TOMDF:SubscriptionAgreementsMember 2020-03-01 2020-03-31 0001645260 us-gaap:InvestorMember TOMDF:SubscriptionAgreementsMember 2020-03-31 0001645260 us-gaap:InvestorMember TOMDF:SubscriptionAgreementsMember 2020-01-01 2020-12-31 0001645260 us-gaap:InvestorMember TOMDF:SubscriptionAgreementsMember 2021-01-01 2021-03-31 0001645260 us-gaap:InvestorMember TOMDF:SubscriptionAgreementsMember 2020-12-31 0001645260 us-gaap:InvestorMember TOMDF:SubscriptionAgreementsMember 2021-03-31 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-03 2020-08-04 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-04 0001645260 TOMDF:OrdinarySharesMember TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-03 2020-08-04 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2021-01-01 2021-09-30 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2021-09-30 0001645260 TOMDF:OrdinarySharesMember 2021-09-30 0001645260 TOMDF:OrdinarySharesMember 2021-01-01 2021-09-30 0001645260 TOMDF:NISMember TOMDF:OrdinarySharesMember 2021-09-30 0001645260 TOMDF:NISMember TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2021-09-30 0001645260 TOMDF:SeveralServiceAgreementsMember 2021-01-01 2021-09-30 0001645260 TOMDF:NISMember TOMDF:SeveralServiceAgreementsMember 2021-09-30 0001645260 us-gaap:SellingAndMarketingExpenseMember TOMDF:SeveralServiceAgreementsMember 2021-01-01 2021-09-30 0001645260 us-gaap:GeneralAndAdministrativeExpenseMember TOMDF:SeveralServiceAgreementsMember 2021-01-01 2021-09-30 0001645260 srt:MaximumMember TOMDF:TwoThousandFifteenIsraeliShareOptionPlanMember 2016-01-10 2016-01-11 0001645260 TOMDF:TwoOfficersMember 2020-07-26 2020-07-29 0001645260 TOMDF:TwoOfficersMember 2020-07-29 0001645260 us-gaap:MeasurementInputExpectedDividendRateMember 2020-07-29 0001645260 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-07-29 0001645260 TOMDF:MeasurementInputRateVolatilityMember 2020-07-29 0001645260 TOMDF:TwoOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-26 2020-07-29 0001645260 us-gaap:RestrictedStockMember TOMDF:PublicOfferingMember 2020-07-26 2020-07-29 0001645260 TOMDF:TwoOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001645260 us-gaap:RestrictedStockMember 2020-07-26 2020-07-29 0001645260 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001645260 srt:ChiefExecutiveOfficerMember 2021-03-09 2021-03-10 0001645260 srt:ChiefExecutiveOfficerMember TOMDF:OneTimeBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefExecutiveOfficerMember us-gaap:DeferredBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember TOMDF:OneTimeBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember us-gaap:DeferredBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember us-gaap:RestrictedStockMember 2021-03-09 2021-03-10 0001645260 srt:DirectorMember 2021-03-09 2021-03-10 0001645260 srt:BoardOfDirectorsChairmanMember 2021-03-09 2021-03-10 0001645260 TOMDF:BreastCancerTestMember 2021-01-01 2021-09-30 0001645260 TOMDF:AlzheimerMember 2021-01-01 2021-09-30 0001645260 TOMDF:COVIDNineteenTestingMember 2021-01-01 2021-09-30 0001645260 TOMDF:BreastCancerTestMember 2021-09-30 0001645260 TOMDF:AlzheimerMember 2021-09-30 0001645260 TOMDF:COVIDNineteenTestingMember 2021-09-30 0001645260 country:IL 2021-01-01 2021-09-30 0001645260 country:IL 2021-07-01 2021-09-30 0001645260 country:IL 2020-01-01 2020-09-30 0001645260 country:IL 2020-07-01 2020-09-30 0001645260 country:US 2021-01-01 2021-09-30 0001645260 country:US 2021-07-01 2021-09-30 0001645260 country:US 2020-01-01 2020-09-30 0001645260 country:US 2020-07-01 2020-09-30 0001645260 country:IL 2021-09-30 0001645260 country:IL 2020-12-31 0001645260 country:US 2021-09-30 0001645260 country:US 2020-12-31 0001645260 TOMDF:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001645260 TOMDF:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001645260 TOMDF:InstitutionalInvestorMember us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember 2021-10-21 0001645260 TOMDF:InstitutionalInvestorMember us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember 2021-10-20 2021-10-21 0001645260 srt:MaximumMember TOMDF:InstitutionalInvestorMember us-gaap:WarrantMember us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember 2021-10-21 0001645260 TOMDF:InstitutionalInvestorMember us-gaap:WarrantMember us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember 2021-10-21 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember 2021-11-21 2021-11-22 iso4217:USD shares iso4217:USD shares TOMDF:Number pure 0001645260 false Q3 --12-31 10-Q true 2021-09-30 2021 false 000-56026 TODOS MEDICAL LTD. L3 121 Derech Menachem Begin 30th Floor Tel Aviv 6701203 IL +972 (52) 642-0126 Yes Yes Non-accelerated Filer true true false false 914387625 166000 935000 2072000 378000 1904000 536000 129000 601000 4271000 2450000 745000 495000 224000 2591000 1999000 182000 361000 591000 7761000 1500000 12890000 3559000 17161000 6009000 1306000 3205000 1672000 1169000 1640000 13000 844000 3450000 2316000 355000 291000 8192000 8069000 17017000 5965000 2000 301000 1873000 2500000 86000 315000 175000 185000 19468000 8951000 0.01 0.01 5000000000 1000000000 874813050 874813050 376335802 376335802 2593000 1059000 58735000 35211000 -71827000 -47281000 -10499000 -11011000 17161000 6009000 7773000 1316000 1010000 1284000 5191000 894000 1043000 883000 2582000 422000 -33000 401000 685000 9655000 166000 9086000 2387000 2187000 429000 757000 5198000 1729000 1869000 804000 -5688000 -13149000 -2497000 -10246000 17360000 11375000 6875000 7055000 -1499000 -734000 -1007000 -734000 -24547000 -25258000 -10379000 -18035000 -0.04 -0.12 -0.01 -0.07 637916356000 210806186000 736939641000 257276039000 103573795 280000 10979000 -17508000 -6249000 17091096 49000 951000 1000000 27336061 78000 1508000 1586000 333000 333000 350000 1000 376000 377000 30000 30000 466000 466000 5718588 17000 815000 832000 -4638000 -4638000 154069540 425000 15458000 -22146000 -6263000 13008976 37000 963000 1000000 13015711 36000 866000 902000 193000 193000 126000 126000 13750000 39000 910000 949000 720000 2000 39000 41000 7309915 21000 966000 987000 -2585000 -2585000 201874142 560000 19521000 -24731000 -4650000 14017973 41000 1413000 1454000 582000 582000 5812500 17000 465000 482000 14437500 43000 1253000 1296000 67599796 193000 5891000 6084000 18608113 54000 946000 1000000 3500000 10000 305000 315000 9333333 27000 1191000 1218000 1000000 3000 -3000 70000 70000 1300000 1300000 460000 460000 57000 57000 -18035000 -18035000 336183357 948000 33451000 -42766000 -8367000 376335802 1059000 35211000 -47281000 -11011000 2500000 8000 -8000 134358817 409000 6461000 6870000 2000000 6000 82000 88000 792000 792000 5229809 16000 239000 255000 20000000 61000 809000 870000 11921053 36000 30000 66000 169000 169000 -17557000 -17557000 552345481 1595000 43785000 -64838000 -19458000 55415011 170000 1606000 1776000 3430000 3430000 21000 21000 1699000 1699000 143000 143000 3390000 3390000 607760492 1765000 50684000 -61448000 -8999000 238190489 739000 7179000 7918000 728000 728000 3000000 9000 76000 85000 25862069 80000 -80000 148000 148000 -10379000 -10379000 -10379000 -10379000 874813050 2593000 58735000 -71827000 -10499000 -24547000 -25258000 556000 38000 53000 29000 633000 2334000 3000000 8157000 2823000 1623000 1499000 -88000 3495000 40000 499000 415000 18080000 8393000 2290000 -299000 3777000 1629000 206000 806000 440000 -704000 -48000 -961000 203000 -857000 -326000 1376000 -9299000 -3667000 965000 346000 5000 450000 -1176000 1024000 560000 -3165000 -1351000 2496000 812000 1249000 1329000 2165000 13687000 3087000 30000 255000 1296000 11695000 5225000 -769000 207000 935000 12000 166000 219000 4157000 948000 -16493000 -3943000 -870000 -6084000 315000 -482000 792000 -450000 2615000 -595000 40000 -18000 183000 3000 168000 7761000 1500000 1250000 4989000 -1699000 -315000 1176000 <p id="xdx_806_eus-gaap--NatureOfOperations_z8SRQJOAxj3b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: 10pt Times New Roman, Times, Serif">NOTE 1 - <span id="xdx_825_zEdCnxNXGPki">GENERAL</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operations</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Todos Medical Ltd. (the “Company” or “Todos”) was incorporated under the laws of the State of Israel and commenced its operations on April 22, 2010. The Company engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Additionally, commencing 2020, the Company through its U.S. subsidiary (Corona Diagnostics, LLC) has entered into several distribution agreements with other companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple third-party manufacturers after completing validation of said testing kits and supplies in certified laboratory in the United States. Additionally, upon completion of the Share Purchase Agreement for the purchase of Provista Diagnostics, Inc. (see B below), the Company, through Provista Diagnostics, Inc. provide diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In December 2020, the Company announced the commercial launch of its proprietary 3CL protease inhibitor dietary supplement Tollovid™. Tollovid, a mix of botanical extracts, is being targeted to support healthy immune function against circulating coronaviruses. Tollovid was granted a Certificate of Free Sale by the US Food and Drug Administration (FDA) in August 2020, allowing its commercial sale anywhere in the United States. In May 2021, the FDA granted the Company a new Certificate of Free Sale for a second dosing regimen for Tollovid™ as a dietary supplement, under which the Company is authorized to market Tollovid with a dosing regimen of 60 pills over a five-day period, equivalent to 12 pills per day.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the period of nine months ended September 30, 2021, all of the revenue resulted from sales of COVID-19 related products and testing kits. Through September 30, 2021, the Company has not yet generated any revenue from its developed cancer-screening tests TMB-1 and TMB-2, LymPro Test™ , or its dietary supplement, Tollovid™.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Share Purchase Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 20pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On April 19, 2021, the Company entered into a Share Purchase Agreement (“SPA”) with Strategic Investment Holdings, LLC, Ascenda BioSciences LLC (“SIH”, “Ascenda” and together referring as “Sellers”, respectively) and Provista Diagnostics, Inc. (“Provista”). Ascenda was the sole owner of the outstanding securities of Provista and SIH is the sole owner of all the outstanding securities of Ascenda. Provista is a medical diagnostics company based in Alpharetta, Georgia that owns the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Subject to the terms and conditions of the SPA, the Company shall purchase from the Sellers <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210417__20210419__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--ProvistaDiagnosticsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pdd" title="Stock issued during period shares purchase">3,599</span> shares of Preferred Stock and <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210417__20210419__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--ProvistaDiagnosticsIncMember__us-gaap--StatementEquityComponentsAxis__custom--OrdinaryStockMember_pdd" title="Stock issued during period shares purchase">1,581</span> shares of Ordinary Stock (collectively the “Provista Shares”) representing <span id="xdx_907_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20210417__20210419__dei--LegalEntityAxis__custom--ProvistaDiagnosticsIncMember_zamE6NALz9C" title="Sale of stock, percentage">100</span>% of Provista’ s securities outstanding, for an aggregate purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210417__20210419__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--ProvistaDiagnosticsIncMember_pn3n3" title="Sale of stock value of shares issued in transaction">7,500</span> subject to the following terms:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On or before April 19, 2021, (the “First Closing Date”), the Company shall deliver to Sellers a non-refundable deposit of $<span id="xdx_908_eus-gaap--Deposits_c20210419_pn3n3" title="Cash deposits">1,250</span> (the “Cash Deposit”). The Cash Deposit was delivered at April 21, 2021.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On or before the First Closing Date, the Company shall deliver to Sellers or Sellers’ designees such number of non-refundable shares of its ordinary stock, par value NIS <span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210930__us-gaap--SubsidiarySaleOfStockAxis__custom--TodosDepositSharesMember_zIEXRRKQJf4k">0.01</span></span><span style="font: 10pt Times New Roman, Times, Serif">, (the “Todos Deposit Shares”) with a fair market value of $<span id="xdx_901_ecustom--FairValueMarketDepositShares_pn3n3_c20210101__20210930__us-gaap--SubsidiarySaleOfStockAxis__custom--TodosDepositSharesMember_zOUItfW0Zpra">1,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">, as defined in the SPA. <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210930__us-gaap--SubsidiarySaleOfStockAxis__custom--TodosDepositSharesMember_ztpW4D8zef5k">25,862,069</span> ordinary shares were delivered in August 2021.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On or before July 1, 2021 (the “Second Closing Date”), the Company shall deliver to the Sellers a second payment of $<span id="xdx_901_eus-gaap--ProceedsFromRepaymentsOfDebt_pn3n3_c20210701__20210702_zXRc550YfDn1">1,250 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(the “Second Cash Payment”). The second payment was made during July 2021.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>4.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company shall have the option of extending the payment of the Second Cash Payment until July 15, 2021, by paying the Sellers an additional amount of $<span id="xdx_900_ecustom--AdditionalAmountOfCashPayment_pn3n3_c20210713__20210715_zjCbpmeoSJN6" title="Additional amount of cash payment">250</span> (the “Extension Payment”) on or before the Second Closing Date. If the Extension Payment is received by Sellers on or before the Second Closing Date, then the Company shall deliver the Convertible Note on the Second Closing Date and the Second Cash Payment on or before July 15, 2021. In the event the Company completes the Second Cash Payment, the aforesaid Extension Payment shall be credited towards the Second Cash Payment. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TODOS MEDICAL LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1 - GENERAL (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>5.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On or before the Second Closing Date, the Company shall deliver to Sellers or their designees the Convertible Note in the principal amount of $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20210702_z7Hn3Tv6iN5k" title="Convertible notes payable">3,500</span>, payable by the Company to the Sellers (the “Note”). At any time or times on or after the issuance sate of the Note, the Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount into fully paid and nonassessable shares of common stock over a period commencing <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20210701__20210702_zqFWTNzwC2l2" title="Maturity date description">October 20, 2021 through April 8, 2025</span> (the “Maturity Date”), at the conversion price equal to the lesser of (i) $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210702_zX1yuLT3HjI2" title="Debt Instrument, Convertible, Conversion Price">0.05</span> or (ii) the volume weighted average price of the last <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uDays_c20210701__20210702_zRN6LjUkGZG" title="Debt instrument trading days">20</span> trading days for the common shares prior to the conversion date (the “Fair Market Value”).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In the event the Sellers deliver a conversion notice to the Company at a per share price less than $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210702__srt--RangeAxis__srt--MinimumMember_zaCCSf9ClUPj" title="Debt Instrument, Convertible, Conversion Price">0.05</span>, the Company shall have the right to immediately notify the Sellers of its intention to pay the conversion amount in cash within 3 business days of receipt of the conversion notice (i.e. before Sellers would take possession of shares converted under the conversion notice). If, at any time between October 20, 2021 and April 20, 2022, the average of the lowest bid and closing sale price is below $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210702__srt--RangeAxis__srt--MinimumMember_zBUAC4zyIoPd" title="Debt Instrument, Convertible, Conversion Price">0.05</span>, the Company has the option to buy out all or any portion of the Note (the “Buyback Option”). In the event the Company exercises the Buyback Option for an amount equal to or greater than $<span id="xdx_905_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn3n3_c20210701__20210702_ztddXA2EkeO6" title="Payments for repurchase amount">1,170</span> (the “Buyback Amount”), the Sellers shall not submit any conversions below $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210702__srt--RangeAxis__srt--MinimumMember_zur2MtZPBtQ8">0.05</span> for 90-days period from receipt of the Buyback Amount (the “90-Days Period”). The Company may exercise a second Buyback Option at the end of the 90-Days Period under the same terms. The Company must provide 30-days’ notice to the Sellers prior to exercising any Buyback Option or notify the Sellers of its intention to pay the Buyback Amount upon receipt of a conversion notice below $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210702__srt--RangeAxis__srt--MinimumMember_z1iavLRFX7M6">0.05</span> and pay the Buyback Amount within 3 business days of receipt of such notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In the event that the Company uplists its shares of common stock to a national securities exchange, the Note shall automatically be exchanged into preferred stock (the “Series B Preferred Stock”) with a conversion price equal to the lesser of (i) $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210702__srt--RangeAxis__srt--MinimumMember_znNscOTSTUBc">0.05</span>, (ii) the opening price on the day of the uplisting provides there is no transaction associated with the uplisting or (iii) the deal price of an uplisting transaction (the “Mandatory Conversion”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If, at any time while this Note is outstanding, (i) the Company effects a Fundamental Transaction, , as defined in the SPA, then, upon any subsequent conversion of this Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of common stock (the “Alternate Consideration”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>6.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s obligation to deliver the Second Cash Payment and the Convertible Note to the Seller at the Second Closing shall be secured by the Provista Shares to be held and released in accordance with the Escrow Agreement and all of Provista’ s assets (the “Assets”) pursuant to the terms of the Security Agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>7.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At the First Closing, the Sellers shall hold full right, title, and interest in and to the Cash Deposit, and the Todos Deposit Shares paid to the Sellers or their designees and/or assignees on the First Closing Date free and clear of all rights, liens and encumbrances, without limitation. Additionally, should the Company fail to deliver the Second Cash Payment and/or the Convertible Note by the Second Closing Date, the Escrow Agent shall return the Provista Shares to the Sellers, and the Sellers shall become the sole owners. The Company further agrees and understands that in the event that the Company fails to deliver the Second Cash Payment and/or the Convertible Note to the Sellers at the Second Closing, the Cash Deposit and the Todos Deposit Shares shall be the property of the Sellers, and the Sellers shall retain and hold full right, title, and interest in and be the sole owners of the Cash Deposit, the Todos Deposit Shares and <span id="xdx_904_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20210417__20210419__dei--LegalEntityAxis__custom--ProvistaDiagnosticsIncMember_zCnjrt1RqzGl">100</span>% of the Provista Shares. In such an event, the Company will have absolutely no rights, claims or interest of any type in connection with the Provista Shares, Cash Deposit or Todos Deposit Shares or this transaction, regardless of any alleged conduct by Seller or anyone else. Further, in such event the Company irrevocably will be deemed to have canceled this Agreement and relinquished all rights in and to the Provista Shares, Cash Deposit and Todos Deposit Shares. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The consummation of the transactions contemplated by the SPA have been taken place as of April 19, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TODOS MEDICAL LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1 - GENERAL (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase price allocation</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Non-refundable shares of its ordinary stock - As agreed in the SPA, the Company committed to issue non-refundable <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_pdd" title="Number of shares issued as non-refundable">29,296,875</span> ordinary stock, par value NIS <span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210930__us-gaap--AwardTypeAxis__custom--ILSMember_zsyULwVA1VAk">0.01</span>. The fair value of the non-refundable shares was estimated as of the Closing Date based on the Company’s share price as quoted in the OTC as of the Closing Date at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20210101__20210930_zWevqC7RCZe1" title="Number of shares issued value">1,699</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the convertible note was estimated by third party appraiser as weighted average of the two possible scenarios of the total loan amount conversion as of April 19, 2021, <span id="xdx_908_eus-gaap--FairValueMeasurementsHighestAndBestUseDescription_c20210414__20210419_zpeug6nZVsoh" title="Fair value description">90% probability for the Mandatory Conversion and 10% probability for the Optional / Maturity Conversion</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfPurchasesPriceAllocationOfConversionTableTextBlock_hus-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember_zKIR8qBu2Dij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Optional / Maturity Conversion (scenario 1) was estimated by the appraiser using the Monte Carlo Simulation Model based on the following parameters:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zxDSnpOVXk34" style="display: none">SCHEDULE OF PURCHASES PRICE ALLOCATION OF CONVERSION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 19, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z4eIpOdIJAE6" style="width: 22%; text-align: right" title="Debt instrument, measurement input">0.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--DebtInstrumentMeasurementInputTerm_pid_dtY_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zsgqDi9tyN8i" title="Debt instrument, measurement input, term">3.94</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKaJA93tznHf" style="text-align: right" title="Debt instrument, measurement input">164.02</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Share price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg9BYxzsbuXf" style="text-align: right" title="Debt instrument, measurement input">0.058</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_fKg_____zQfLZpU8BTjg" style="display: none" title="Debt instrument, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></span><span id="xdx_F27_zRExZ9U0HTR6" style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember_zrsLLu5viigh" style="text-align: right" title="Fair value">5,101</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zrmOB9dt4FY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F03_zra70zaEKdT8" style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z1V5wWxZPCK" style="font: 10pt Times New Roman, Times, Serif">The lower of (i) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember_zPoAfqjMYG13" title="Debt Instrument, Convertible, Conversion Price">0.05</span> (ii) the volume weighted average price (VWAP) of the last <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uDays_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember_zNVJAWL5bPk" title="Debt Instrument, Convertible, Threshold Consecutive Trading Days">20</span> trading days for the Ordinary Stock as reported in the OTC market prior to the conversion.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F03_zARAjhIxMPPc" style="font: 10pt Times New Roman, Times, Serif">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_ziPXF0hoglD1" style="font: 10pt Times New Roman, Times, Serif">The lower of (i) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember_zRYb9SQk8ylb" title="Debt Instrument, Convertible, Conversion Price">0.05</span> (ii) the volume weighted average price (VWAP) of the last <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uDays_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember_zPfjC9iCKBvg" title="Debt Instrument, Convertible, Threshold Consecutive Trading Days">20</span> trading days for the Ordinary Stock as reported in the OTC market prior to the conversion.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89D_ecustom--ScheduleOfPurchasesPriceAllocationOfConversionTableTextBlock_hus-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationsModelMember_zTCpRallSRS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Mandatory Conversion (scenario 2) was estimated by the appraiser using the Monte Carlo Simulation Model based on the following parameters:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B4_zg2sQak3xpGe" style="display: none">SCHEDULE OF PURCHASES PRICE ALLOCATION OF CONVERSION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 19, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zkP5lrm0hTal" style="width: 22%; text-align: right" title="Debt instrument, measurement input">0.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--DebtInstrumentMeasurementInputTerm_dtY_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z9MWdHNcw9i4" title="Debt instrument, measurement input, term">0.04</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJh1Olq6sTC4" style="text-align: right" title="Debt instrument, measurement input">112.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Share price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zIKTIs4JJkaa" style="text-align: right" title="Debt instrument, measurement input">0.058</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_fKg_____zxjVE6dnVbO4" style="display: none" title="Debt instrument, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></span><span id="xdx_F2B_z5NNC7VTu41e" style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleDebtFairValueDisclosures_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember_pn3n3" style="text-align: right" title="Fair value">4,976</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_znRJvuOtHd21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0A_z8LYHAOKX3oh" style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_z0B4T0zerJMj" style="font: 10pt Times New Roman, Times, Serif">The lower of (i) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember_zN6LdX6ptar3" title="Debt Instrument, Convertible, Conversion Price">0.05</span> (ii) the volume weighted average price (VWAP) of the last <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uDays_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember_zNONU1Ie4qgg" title="Debt Instrument, Convertible, Threshold Consecutive Trading Days">20</span> trading days for the Ordinary Stock as reported in the OTC market prior to the conversion.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F09_zSp3RVYw3d47" style="font: 10pt Times New Roman, Times, Serif">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zzZhMxUtJVlh" style="font: 10pt Times New Roman, Times, Serif">The lower of (i) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember_zTatJGDFl0l6" title="Debt Instrument, Convertible, Conversion Price">0.05</span> (ii) the volume weighted average price (VWAP) of the last <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBVUkNIQVNFUyBQUklDRSBBTExPQ0FUSU9OIE9GIENPTlZFUlNJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uDays_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember_zciAzkwkvhU3" title="Debt Instrument, Convertible, Threshold Consecutive Trading Days">20</span> trading days for the Ordinary Stock as reported in the OTC market prior to the conversion.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the convertible component was estimated by the third-party appraiser after giving effect to the weighted average of the two possible scenarios as of issuance dates was $<span id="xdx_906_eus-gaap--ConvertibleDebtFairValueDisclosures_c20210930__us-gaap--RelatedPartyTransactionAxis__custom--ThirdPartyMember_pn3n3" title="Fair value of convertible debt">4,989</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_ecustom--BusinessCombinationPurchasePriceAllocationTableTextBlock_zgnhvR8Yypjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the total purchase price and purchase price allocation:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zROG0gk9ebya" style="display: none">SCHEDULE OF PURCHASE PRICE ALLOCATION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"><b>Unaudited</b></td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Cash payment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20210101__20210930_zTUWBXEbccCd" style="width: 16%; text-align: right" title="Cash payment">2,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Consideration in Shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--BusinessCombinationSharesConsideration_pn3n3_c20210101__20210930_z0vlcR6Ubang" style="text-align: right" title="Consideration in Shares">1,699</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of convertible promissory note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--BusinessCombinationFairValueOfConvertiblePromissoryNote_pn3n3_c20210101__20210930_zEqSrvtzxYfd" style="text-align: right" title="Fair value of convertible promissory note">4,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total purchase price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--BusinessCombinationConsiderationPurchaseprice_pn3n3_c20210101__20210930_zmWcbD6acG96" style="text-align: right" title="Total purchase price">9,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cash and cash equivalents</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20210930_z1YegXRzTzb1" style="text-align: right" title="Cash and cash equivalents">73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trade receivables</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210930_pn3n3" style="text-align: right" title="Trade receivables">66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c20210930_pn3n3" style="text-align: right" title="Property and equipment, ne">183</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Security deposit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDeposit_c20210101__20210930_pn3n3" style="text-align: right" title="Security deposit">3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Technology intangible asset</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTechnology_c20210930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Technology intangible asset">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total identifiable assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20210930_zemkF0l1tra4" style="text-align: right" title="Total identifiable assets">1,825</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pn3n3_di_c20210930_z7oNN5kJSjrc" style="text-align: right" title="Accounts payable">(82</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Deferred tax liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_pn3n3_di_c20210930_z3B12IGCZaQj" style="text-align: right" title="Deferred tax liability">(315</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Due to related party</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_iNI_pn3n3_di_c20210930_z8OZcfSRKB2" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related party">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: justify">Total liability assumed</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iNI_pn3n3_di_c20210930_zVjO7Ie2LQOd" style="border-bottom: Black 1pt solid; text-align: right" title="Total liability assumed">(398</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Total goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--Goodwill_c20210930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total pro forma goodwill">7,761</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_z3zqEAAmERed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TODOS MEDICAL LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1 - GENERAL (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unaudited pro forma results of operations for the nine months ended September 30, 2021 and for the year ended December 31, 2020 are included below as if the acquisition of the Provista’s business occurred on January 1, 2020. This summary of the unaudited pro forma results of operations is not necessarily indicative of what the Company’s results of operations would have been had the Provista Business been acquired at the beginning of 2020, nor does it purport to represent results of operations for any future periods.</span></p> <p id="xdx_890_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zLzgrpHwSmKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B2_zdB30zDZAUe9" style="display: none">SCHEDULE OF UNAUDITED PRO FORMA RESULTS OF OPERATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20210101__20210930_z3FvOERRoSma" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20200101__20201231_zt4STqDtUZ0l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_zY2Vfw1yMmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zCKD0S4wfGP9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,552</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17,603</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_pid_zQyMkacO1dr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8AB_zDkiTtBQSF03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>D.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Foreign operations</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Todos Medical (Singapore) Pte Ltd</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On January 27, 2016, the Company incorporated a wholly owned subsidiary in Singapore under the name of Todos Medical (Singapore) Pte Ltd. (“Todos Singapore”) for the purpose of advancing clinical trials of the Company’s core technology for breast cancer in Southeast Asia. As of September 30, 2021, Todos Singapore has not yet commenced its business operations.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Todos Medical USA </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2020, the Company incorporated a U.S. subsidiary named Todos Medical USA (“Todos U.S.”) for the purpose of conducting business as medical importer and distributor focused on the distribution of the Company’s testing products and services to customers in the North America and Latin America. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Corona Diagnostics, LLC</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In April 2020, the Company incorporated a U.S. subsidiary named Corona Diagnostics, LLC (“Corona Diagnostics”) for the purpose of marketing COVID-19 related products in the United States to validate potential products the Company is contemplating distributing and creating marketing materials for the testing products based upon those validations.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>4.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Breakthrough Diagnostics, Inc.</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">On February 27, 2019, the Company entered into Shares Purchase and Assignment of License Agreement with Amarantus Bioscience Holdings, Inc. (“Amarantus”), under which the Company purchased <span id="xdx_903_ecustom--PercentageOfIssuedAndOutstandingCommonStock_iI_pid_dp_c20190227__dei--LegalEntityAxis__custom--BreakthroughDiagnosticsIncMember_zn8IVLRNCeJh">19.99</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the issued and outstanding common stock of Breakthrough Diagnostics, Inc. (“Breakthrough”) for entering into the field of early detection of Alzheimer’s disease. On July 28, 2020, the Company entered into Amendment No. 1 to the Shares Purchase and Assignment of License Agreement with Amarantus, pursuant to which the Company completed the purchase of the remaining <span id="xdx_90C_ecustom--RemainingPercentageOfIssuedAndOutstandingCommonStock_iI_pid_dp_c20200728__dei--LegalEntityAxis__custom--BreakthroughDiagnosticsIncMember_zZ3A51JR3fr1">80.01</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the issued and outstanding common stock of Breakthrough for consideration that was based on the Company’s shares.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">At the Closing Date, Breakthrough was determined to be excluding substantive process as required under the definition of business in accordance with the provisions of ASC Topic 805 “Business Combination”. In addition, it was determined that the License represents IPR&amp;D with no alternative future use and therefore the entire purchase price allocated to the acquired IPR&amp;D was charged to expense at the acquisition date as part of “Research and Development expenses” line in operations in the accompanying consolidated statement of operations for the year ended December 31, 2020. </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>5.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other entities</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In June 2020, the Company entered into an agreement with NLC Pharma Ltd., under which Antigen COVID Test Killer was formed for the purpose of developing the diagnostic candidate Antigen Killer and product commercialization through the Company’s sales channels. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In August 2020, the Company entered into an agreement with Care GB Plus Ltd, under which Bio Imagery Ltd. (“Bio Imagery”) has been incorporated for the purpose of developing, marketing and commercializing the Products and all the Intellectual Property of the Company (“Todos Cancer Assets”) and to develop new Intellectual Property, products and services, and pursue the business based on the Todos Cancer Assets and on new intellectual property that will be developed by Bio Imagery. As of September 30, 2021, Bio Imagery has not yet commenced its business operations and the Company wrote off its investment in the amount of $<span id="xdx_906_ecustom--InvestmentWriteOff_pn3n3_c20200801__20200831_zdEv2S5bF6vi" title="investment write off">618</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: 7.65pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: 7.65pt"><span style="font: 10pt Times New Roman, Times, Serif">The Company and its entities herein considered as the “Group”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>6.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>Provista Diagnostics, Inc </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">See note 1B and 1C above</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TODOS MEDICAL LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: 10pt Times New Roman, Times, Serif">NOTE 1 - GENERAL (Cont.)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>E.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Going concern uncertainty</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has devoted substantially all of its efforts to research and development of its cancer and other disease diagnostics products and raising capital to fund this development, along with its dietary supplement distribution. The development and commercialization of the Company’s products are expected to require substantial further expenditures. To date, the Company has not yet generated sufficient revenues from operations to support its activities, and therefore it is dependent upon external sources for financing its operations. Since inception through September 30, 2021, the Company has incurred accumulated losses of $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20210930_zzuvbSxAzEF4">71,827</span></span><span style="font: 10pt Times New Roman, Times, Serif">. As of September 30, 2021, the Company’s current liabilities exceed its current assets by $<span id="xdx_90D_ecustom--WorkingCapital_iI_pn3n3_c20210930_zjoI1cR0PmOc" title="Working capital">3,921</span>,</span><span style="font: 10pt Times New Roman, Times, Serif"> and there is a shareholders’ deficit of $<span id="xdx_900_eus-gaap--StockholdersEquity_iNI_pn3n3_di_c20210930_zvyl0waN3uJ8">10,499</span></span><span style="font: 10pt Times New Roman, Times, Serif">. The Company has generated negative operating cash flow for all periods. Management has considered the significance of such condition in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company plans to finance its operations through the sale of equity and to the extent available, short term and long-term loans (including through issuance of convertible loans together with other financial instruments) and also through revenues from sales of corona testing related products. There can be no assurance that the Company will succeed in obtaining the necessary financing or generating revenues from product sales to continue its operations as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2020, the Company raised net amounts of $<span id="xdx_901_ecustom--ProceedsFromIssuanceOfFinancialInstruments_pn3n3_c20200101__20201231_zTkuK0Ag9S15" title="Proceeds from issuance of financial instruments">10,685 </span></span><span style="font: 10pt Times New Roman, Times, Serif">through receivables financing facility, straight loans, private placement transactions (including equity line), and convertible bridge loans transactions. During the period of nine months ended September 30, 2021, the Company raised net amounts of $<span id="xdx_904_ecustom--ProceedsFromIssuanceOfFinancialInstruments_pn3n3_c20210101__20210930_zL2yzTgDqL41">16,438</span>,</span><span style="font: 10pt Times New Roman, Times, Serif"> through straight loans, convertible bridge loans transactions and private placement transaction. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>F.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risk factors</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As described in the above paragraph, the Company has a limited operating history and faces a number of risks and uncertainties, including risks and uncertainties regarding to potential dispute which related to commercial terms in connection with unpaid invoices (related to sales, net yet recognized as revenue) with one of its significant clients</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>G.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>COVID-19</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak has reached all of the regions in which the Company does business, and governmental authorities around the world have implemented numerous measures attempting to contain and mitigate the effects of the virus, including travel bans and restrictions, border closings, quarantines, shutdowns, limitations or closures of non-essential businesses, and social distancing requirements.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The global spread of COVID-19 and actions taken in response have caused and may continue to cause disruptions and/or delays in our supply chain and shipments and caused significant economic and business disruption to the Company’s customers and vendors.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The COVID-19 pandemic has created and may continue to create significant opportunity under the uncertainty in macroeconomic conditions, which may cause further demand for the Company’s core business related to PCR testing kits and related materials and supplies as already reflected by recognized revenues of $<span id="xdx_906_ecustom--RecognizedRevenue_c20200101__20201231_pn3n3" title="Recognized revenue">5,031</span> and $<span id="xdx_90C_ecustom--RecognizedRevenue_c20210101__20210930_pn3n3" title="Recognized revenue">7,733</span> during the year ended December 31, 2020 and the period of nine months ended September 30, 2021, respectively, substantially all of which was generated after July 2020. However, the Company may face uncertainties around its estimates of revenue collectability and accounts receivable credit losses and its expectation to receive funds from external sources for financing its operations. The Company expects uncertainties around its key accounting estimates to continue to evolve depending on the duration and degree of impact associated with the COVID-19 pandemic. The Company estimates may change as new events occur and additional information emerges, and such changes are recognized or disclosed in the Company’s consolidated financial statements.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> 3599 1581 1 7500000 1250000 0.01 1500000 25862069000 1250000 250000 3500000 October 20, 2021 through April 8, 2025 0.05 20000 0.05 0.05 1170000 0.05 0.05 0.05 1 29296875 0.01 1699000 90% probability for the Mandatory Conversion and 10% probability for the Optional / Maturity Conversion <p id="xdx_89A_ecustom--ScheduleOfPurchasesPriceAllocationOfConversionTableTextBlock_hus-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember_zKIR8qBu2Dij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Optional / Maturity Conversion (scenario 1) was estimated by the appraiser using the Monte Carlo Simulation Model based on the following parameters:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zxDSnpOVXk34" style="display: none">SCHEDULE OF PURCHASES PRICE ALLOCATION OF CONVERSION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 19, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z4eIpOdIJAE6" style="width: 22%; text-align: right" title="Debt instrument, measurement input">0.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--DebtInstrumentMeasurementInputTerm_pid_dtY_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zsgqDi9tyN8i" title="Debt instrument, measurement input, term">3.94</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKaJA93tznHf" style="text-align: right" title="Debt instrument, measurement input">164.02</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Share price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg9BYxzsbuXf" style="text-align: right" title="Debt instrument, measurement input">0.058</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_fKg_____zQfLZpU8BTjg" style="display: none" title="Debt instrument, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></span><span id="xdx_F27_zRExZ9U0HTR6" style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--OptionalOrMaturityConversionMember_zrsLLu5viigh" style="text-align: right" title="Fair value">5,101</td><td style="text-align: left"> </td></tr> </table> 0.54 P3Y11M8D 164.02 0.058 5101000 0.05 20000 0.05 20000 <p id="xdx_89D_ecustom--ScheduleOfPurchasesPriceAllocationOfConversionTableTextBlock_hus-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationsModelMember_zTCpRallSRS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Mandatory Conversion (scenario 2) was estimated by the appraiser using the Monte Carlo Simulation Model based on the following parameters:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B4_zg2sQak3xpGe" style="display: none">SCHEDULE OF PURCHASES PRICE ALLOCATION OF CONVERSION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 19, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zkP5lrm0hTal" style="width: 22%; text-align: right" title="Debt instrument, measurement input">0.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--DebtInstrumentMeasurementInputTerm_dtY_c20210414__20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z9MWdHNcw9i4" title="Debt instrument, measurement input, term">0.04</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJh1Olq6sTC4" style="text-align: right" title="Debt instrument, measurement input">112.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Share price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zIKTIs4JJkaa" style="text-align: right" title="Debt instrument, measurement input">0.058</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_fKg_____zxjVE6dnVbO4" style="display: none" title="Debt instrument, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></span><span id="xdx_F2B_z5NNC7VTu41e" style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleDebtFairValueDisclosures_c20210419__us-gaap--ValuationTechniqueAxis__custom--MonteCarloSimulationModelMember__us-gaap--DebtInstrumentAxis__custom--MandatoryConversionMember_pn3n3" style="text-align: right" title="Fair value">4,976</td><td style="text-align: left"> </td></tr> </table> 0.54 P0Y14D 112.1 0.058 4976000 0.05 20000 0.05 20000 4989000 <p id="xdx_893_ecustom--BusinessCombinationPurchasePriceAllocationTableTextBlock_zgnhvR8Yypjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the total purchase price and purchase price allocation:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zROG0gk9ebya" style="display: none">SCHEDULE OF PURCHASE PRICE ALLOCATION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"><b>Unaudited</b></td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Cash payment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20210101__20210930_zTUWBXEbccCd" style="width: 16%; text-align: right" title="Cash payment">2,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Consideration in Shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--BusinessCombinationSharesConsideration_pn3n3_c20210101__20210930_z0vlcR6Ubang" style="text-align: right" title="Consideration in Shares">1,699</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of convertible promissory note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--BusinessCombinationFairValueOfConvertiblePromissoryNote_pn3n3_c20210101__20210930_zEqSrvtzxYfd" style="text-align: right" title="Fair value of convertible promissory note">4,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total purchase price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--BusinessCombinationConsiderationPurchaseprice_pn3n3_c20210101__20210930_zmWcbD6acG96" style="text-align: right" title="Total purchase price">9,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cash and cash equivalents</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20210930_z1YegXRzTzb1" style="text-align: right" title="Cash and cash equivalents">73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trade receivables</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210930_pn3n3" style="text-align: right" title="Trade receivables">66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c20210930_pn3n3" style="text-align: right" title="Property and equipment, ne">183</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Security deposit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDeposit_c20210101__20210930_pn3n3" style="text-align: right" title="Security deposit">3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Technology intangible asset</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTechnology_c20210930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Technology intangible asset">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total identifiable assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20210930_zemkF0l1tra4" style="text-align: right" title="Total identifiable assets">1,825</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pn3n3_di_c20210930_z7oNN5kJSjrc" style="text-align: right" title="Accounts payable">(82</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Deferred tax liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_pn3n3_di_c20210930_z3B12IGCZaQj" style="text-align: right" title="Deferred tax liability">(315</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Due to related party</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_iNI_pn3n3_di_c20210930_z8OZcfSRKB2" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related party">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: justify">Total liability assumed</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iNI_pn3n3_di_c20210930_zVjO7Ie2LQOd" style="border-bottom: Black 1pt solid; text-align: right" title="Total liability assumed">(398</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Total goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--Goodwill_c20210930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total pro forma goodwill">7,761</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 2500000 1699000 4989000 9188000 73000 66000 183000 3000 1500000 1825000 82000 315000 1000 398000 7761000 <p id="xdx_890_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zLzgrpHwSmKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B2_zdB30zDZAUe9" style="display: none">SCHEDULE OF UNAUDITED PRO FORMA RESULTS OF OPERATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20210101__20210930_z3FvOERRoSma" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20200101__20201231_zt4STqDtUZ0l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_zY2Vfw1yMmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zCKD0S4wfGP9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,552</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17,603</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_pid_zQyMkacO1dr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td></tr> </table> 7866000 5164000 -24552000 -17603000 -0.04 -0.04 0.1999 0.8001 618000 -71827000 3921000 -10499000 10685000 16438000 5031000 7733000 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zBgklVTQIdm1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2 - <span id="xdx_82B_zZWbIkItDtE9">SIGNIFICANT ACCOUNTING POLICIES </span></b></span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQw8i5v8u4s8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_869_z5DPUx2l4fc8">Basis of presentation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on April 21, 2021 (the “2020 Form 10-K”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The results for the nine and three months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any future period.</span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zvxiIqBe7tb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_860_zgj3aUTcUvBk">Use of estimates in the preparation of financial statements</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions include (i) identification of and measurement of financial instruments in funding transactions; (ii) initial measurement of investment in affiliated companies and subsequent equity method implications; (iii) determination whether an acquired company or formed entities represents a ‘business’; (iv) determination whether acquired or formed entities are considered Variable Interest Entities (VIE) and if so, whether the Group is its Primary Beneficiary (PB) and (v) measurement of the fair value of equity awards.</span></p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z72gZRYeYjOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86D_zGcIMe9O3hBc">Principles of Consolidation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and when applicable its majority owned entities that were determined to be VIE and that the Group was determined as their Primary Beneficiary (PB). Intercompany transactions and balances have been eliminated upon consolidation.</span></p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zW38wbJXj3C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>D.</b></span></td> <td style="text-align: left"><span id="xdx_863_zfWTHnpwKXjj" style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill </b></span><span style="font: 10pt Times New Roman, Times, Serif"><b>and intangible assets</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in business combinations accounted for in accordance with the “purchase method” and is allocated to reporting units at acquisition. Goodwill is not amortized but rather tested for impairment at least annually in accordance with the provisions of ASC Topic 350, “Intangibles - Goodwill and Other”. The Company performs its goodwill annual impairment test for the reporting units at December 31 of each year, or more often if indicators of impairment are present.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Intangible assets with finite lives are amortized using the straight-line basis over their useful lives, to reflect the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up.</span></td></tr> </table> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zSjTqQ2CsLhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>E.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86C_zE4f04qmA2O8">Basic and diluted net loss per ordinary share</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company computes net loss per share in accordance with ASC 260, “Earning per Share”, which requires presentation of both basic and diluted loss per share on the face of the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic net loss per ordinary share is computed by dividing the net loss for the period applicable to ordinary shareholders, by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to stock options and certain stock warrants (accounted for as derivative liability) and using the if-converted method with respect to convertible bridge loans and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zgz733BdELCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The net loss and the weighted average number of shares used in computing basic and diluted net loss per share for the period of nine month ended September 30, 2021 and 2020, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zRPQ1IBTthh2" style="display: none">SCHEDULE OF WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20210101__20210930_zKruNaHmsbCe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20200101__20200930_zBTPyby1XTR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Nine month period ended</p> <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z050WwFKcAnl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,547</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,258</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--RevaluationOfLiabilityRelatedToWarrantsToPurchaseSharesOfCommonStock_zIWA84CRUpRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Revaluation of liability related to warrants to purchase shares of common <br/>Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1120"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1121"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_pn3n3_z2JCCxwPMr41" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,547</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Shares of common stock used in computing basic net loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637,916,356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,806,186</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Incremental shares from assumed exercise of warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1129"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1130"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Shares of common stock used in computing diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">637,916,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">210,806,186</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDiluted_iN_pid_di_zEX3A6TYKxle" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share of common stock, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zEW75bOiBHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021 and 2020 the total weighted average number of potentially dilutive ordinary shares related to outstanding stock options, stock warrants and convertible bridge loans excluded from the calculation of the diluted loss per share was <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zfzzUdqMvXGj" title="Total weighted average number of potentially dilutive ordinary shares">452,109,492</span> and <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zWXF8RnCWjgj" title="Total weighted average number of potentially dilutive ordinary shares">48,642,797</span>, respectively.</span></p> <p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_z0UdmBKpKY74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>F.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zls31Ec0VRnl">Leases</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9xdi1KZAXAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>G.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86A_zITFfrGIeJni">Recent Accounting Pronouncements</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”) which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generall4y will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission) and other non-SEC reporting entities to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company is currently assessing the impact the guidance will have on its condensed consolidated financial statements.</span></p> <p id="xdx_85C_zL48lgi8NpAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQw8i5v8u4s8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_869_z5DPUx2l4fc8">Basis of presentation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on April 21, 2021 (the “2020 Form 10-K”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The results for the nine and three months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any future period.</span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zvxiIqBe7tb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_860_zgj3aUTcUvBk">Use of estimates in the preparation of financial statements</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions include (i) identification of and measurement of financial instruments in funding transactions; (ii) initial measurement of investment in affiliated companies and subsequent equity method implications; (iii) determination whether an acquired company or formed entities represents a ‘business’; (iv) determination whether acquired or formed entities are considered Variable Interest Entities (VIE) and if so, whether the Group is its Primary Beneficiary (PB) and (v) measurement of the fair value of equity awards.</span></p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z72gZRYeYjOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86D_zGcIMe9O3hBc">Principles of Consolidation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and when applicable its majority owned entities that were determined to be VIE and that the Group was determined as their Primary Beneficiary (PB). Intercompany transactions and balances have been eliminated upon consolidation.</span></p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zW38wbJXj3C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>D.</b></span></td> <td style="text-align: left"><span id="xdx_863_zfWTHnpwKXjj" style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill </b></span><span style="font: 10pt Times New Roman, Times, Serif"><b>and intangible assets</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in business combinations accounted for in accordance with the “purchase method” and is allocated to reporting units at acquisition. Goodwill is not amortized but rather tested for impairment at least annually in accordance with the provisions of ASC Topic 350, “Intangibles - Goodwill and Other”. The Company performs its goodwill annual impairment test for the reporting units at December 31 of each year, or more often if indicators of impairment are present.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Intangible assets with finite lives are amortized using the straight-line basis over their useful lives, to reflect the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up.</span></td></tr> </table> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zSjTqQ2CsLhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>E.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86C_zE4f04qmA2O8">Basic and diluted net loss per ordinary share</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company computes net loss per share in accordance with ASC 260, “Earning per Share”, which requires presentation of both basic and diluted loss per share on the face of the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic net loss per ordinary share is computed by dividing the net loss for the period applicable to ordinary shareholders, by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to stock options and certain stock warrants (accounted for as derivative liability) and using the if-converted method with respect to convertible bridge loans and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zgz733BdELCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The net loss and the weighted average number of shares used in computing basic and diluted net loss per share for the period of nine month ended September 30, 2021 and 2020, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zRPQ1IBTthh2" style="display: none">SCHEDULE OF WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20210101__20210930_zKruNaHmsbCe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20200101__20200930_zBTPyby1XTR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Nine month period ended</p> <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z050WwFKcAnl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,547</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,258</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--RevaluationOfLiabilityRelatedToWarrantsToPurchaseSharesOfCommonStock_zIWA84CRUpRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Revaluation of liability related to warrants to purchase shares of common <br/>Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1120"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1121"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_pn3n3_z2JCCxwPMr41" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,547</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Shares of common stock used in computing basic net loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637,916,356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,806,186</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Incremental shares from assumed exercise of warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1129"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1130"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Shares of common stock used in computing diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">637,916,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">210,806,186</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDiluted_iN_pid_di_zEX3A6TYKxle" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share of common stock, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zEW75bOiBHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021 and 2020 the total weighted average number of potentially dilutive ordinary shares related to outstanding stock options, stock warrants and convertible bridge loans excluded from the calculation of the diluted loss per share was <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zfzzUdqMvXGj" title="Total weighted average number of potentially dilutive ordinary shares">452,109,492</span> and <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zWXF8RnCWjgj" title="Total weighted average number of potentially dilutive ordinary shares">48,642,797</span>, respectively.</span></p> <p id="xdx_893_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zgz733BdELCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The net loss and the weighted average number of shares used in computing basic and diluted net loss per share for the period of nine month ended September 30, 2021 and 2020, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zRPQ1IBTthh2" style="display: none">SCHEDULE OF WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20210101__20210930_zKruNaHmsbCe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20200101__20200930_zBTPyby1XTR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Nine month period ended</p> <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z050WwFKcAnl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,547</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,258</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--RevaluationOfLiabilityRelatedToWarrantsToPurchaseSharesOfCommonStock_zIWA84CRUpRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Revaluation of liability related to warrants to purchase shares of common <br/>Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1120"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1121"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_pn3n3_z2JCCxwPMr41" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,547</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Shares of common stock used in computing basic net loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637,916,356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,806,186</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Incremental shares from assumed exercise of warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1129"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1130"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Shares of common stock used in computing diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">637,916,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">210,806,186</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDiluted_iN_pid_di_zEX3A6TYKxle" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share of common stock, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -24547000 -25258000 24547000 25258000 637916356000 210806186000 637916356000 210806186000 -0.04 -0.12 452109492 48642797 <p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_z0UdmBKpKY74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>F.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zls31Ec0VRnl">Leases</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9xdi1KZAXAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>G.</b></span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86A_zITFfrGIeJni">Recent Accounting Pronouncements</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”) which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generall4y will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission) and other non-SEC reporting entities to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company is currently assessing the impact the guidance will have on its condensed consolidated financial statements.</span></p> <p id="xdx_80E_ecustom--SignificantTransactionsDisclosureTextBlock_zB1hXLjVtFB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3 - <span id="xdx_823_ztSTKULrecEh">SIGNIFICANT TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Secured Convertible Equipment Loan Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">On December 31, 2020 (the “Effective Date”), the Company entered into Secured Convertible Equipment Loan Agreement with a private lender (the “Lender”), under which at the Effective Date and for the purpose for purchasing two Liquid Handler Machines (the “Collateral”) to be placed in the laboratory of a Company’s client, the Company will receive from the Lender a net cash amount of $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_pn3n3_c20201230__20201231__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_zdQ4oqZHN7S3" title="Proceeds from loans">450</span> which is including an original issue discount at the rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20201231__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_zVNVsXCFVjA6" title="Debt instrument original issue discount, rate">40</span>% valued at $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201231__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_pn3n3" title="Original issue discount on loan">300</span>, representing a face value of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_pn3n3" title="Debt instrument, face amount">750</span> for the loan (the “Aggregate Loan Principal Amount”). In addition, the Company incurred incremental and direct costs of $<span id="xdx_907_ecustom--IncurredIncrementalAndDirectCosts_c20201231__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_pn3n3" title="Incurred incremental and direct costs">54</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">In addition, under the terms of the Secured Convertible Equipment Loan Agreement, the Lender will be entitled to receive a royalty at a rate of <span title="Royalty interest rate"><span id="xdx_905_ecustom--RoyaltyInterestRate_pid_dp_uPure_c20201230__20201231__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_zXrGEZgyLLyi" title="Royalty interest rate">12.5%</span> of all amounts resulting from any diagnostic tests performed by the two liquid handler machines. During the initial payback period and up until the earlier of either (a) April 30, 2021, or (b) the aggregate loan amount is paid in full, all royalty payments made to Lender will be counted towards their loan balance. Thereafter, the royalties continue so long as the machines are in use.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Aggregate Loan Principal Amount was received in January 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has determined that its obligation for future royalties under the Secured Convertible Equipment Loan Agreement represent contingent interest feature. However, it was determined that such feature is not required to be bifurcated and accounted for as derivatives, as they are eligible for the scope exception prescribed under ASC Topic 815-10-15-59 (d) with respect to certain contracts that are not traded on an exchange, as the underlying is an entity specific performance measure. Accordingly, the obligation for future royalties was accounted for in accordance with the provisions of ASC Topic 450, Contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">As the secured loan upon its original term does not include conversion feature (such feature will only become applicable as a penalty, upon the Company’s failure to repay the Aggregate Loan Principal Amount by the Maturity Date), the liability was accounted for using the effective interest method over the term of the loans until their stated Maturity Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The total discount amortization expenses of $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pn3n3_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_zv8e7OAcNAS3">2,414</span> and $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pn3n3_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_zwrbBoVRedNe">2,207</span>, were </span><span style="font: 10pt Times New Roman, Times, Serif">recorded as part of “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine and three months ended September 30, 2021, respectively. During the three months ended September 30, 2021 the lender converted the entire loan amount into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfkOy5BfJAPl">81,736,111</span> </span><span style="font: 10pt Times New Roman, Times, Serif">ordinary shares of the Company with aggregated value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn3n3_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbj9HK7y3526" title="Shares issued on conversion">750</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities Purchase Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">On January 22, 2021, the Company entered into a Securities Purchase Agreement with Yozma Global Genomic Fund 1 (“Yozma”) pursuant to which Yozma purchased from Todos a convertible note in the original principal amount of up to $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_pn3n3" title="Debt instrument, face amount">4,857</span>. The original principal amount has been originally issued with <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zMENZwNLah2l" title="Debt instrument original issue discount, rate">30</span>% discount of aggregated amount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_pn3n3" title="Original issue discount on loan">1,457</span>, bearing per annum interest at a flat rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_ztMA4JYHRML2" title="Debt instrument, interest rate">4</span>% (the “Interest”) until it becomes due and payable, whether upon the maturity date, which is <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zc7ze6oWKo76" title="Debt instrument maturity date">January 22, 2022</span>, acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof) (the “Maturity Date”). In addition, the outstanding principal amount to be converted, redeemed or otherwise with respect to which this determination is being made and the accrued and unpaid Interest with respect to such outstanding principal amount shall be converted into shares of the Company at conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zxVHU326lWna" title="Debt Instrument, Convertible, Conversion Price">0.07161</span> (the “Conversion Price”). Subsequent to the effective date of the registration statement registering for resale the Conversions Shares and the Warrant Shares pursuant to the Purchase Agreement, if the closing sale price of the Common Stock averages less than the then Conversion Price over a period of <span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uDays_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zybn01TUUWy2" title="Debt instrument, trading days">10</span> consecutive trading days, the Conversion Price shall reset to such average price. If the 10-day volume weighted average price of the Common Stock continues to be less than the Conversion Price, then the Conversion Price should reset to such 10-day average price with a maximum of a <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_dp_uPure_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zfbxC3UIaaLl" title="Debt instrument conversion price, rate">20</span>% discount from the initial Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">At the Company’s option and upon 30 days’ notice to Yozma, <span id="xdx_900_eus-gaap--DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_pid_dp_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zXoUQAigX019" title="Debt unpaid loan, interest rate">33</span>% of the outstanding Principal and accrued and unpaid Interest of the Note (the “Repayment Amount”) may be redeemed at any time at an amount equal to <span id="xdx_90E_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zdnssDleKPbi" title="Debt instrument repayment rate">115</span>% of the Repayment Amount. The foregoing notwithstanding, Yozma may convert any or all of the Note into shares of Common Stock at any time. Through September 30, 2021, the Company has not redeemed any of the outstanding principal amount and accrued interest, and Yozma has not converted any portion of the Note into shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3 - SIGNIFICANT TRANSACTIONS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities Purchase Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">At any time after Yozma becoming aware of an Event of Default as defined in the Securities Purchase Agreement, Yozma may require the Company to redeem (an “Event of Default Redemption”) all or any portion of the Note in cash by wire transfer of immediately available funds at a price equal to principal amount plus interest calculated from the Event of Default at the greater of the default interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_pid_dp_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__srt--RangeAxis__srt--MaximumMember_zlcYBb5euukb" title="Debt unpaid loan, interest rate">18</span>% per annum or the maximum rate permitted under applicable law (the “Event of Default Redemption Price”) together with liquidated damages of $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_pn3n3" title="Liquidation damages, value">250</span> plus an amount in cash equal to <span id="xdx_909_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__srt--RangeAxis__srt--MaximumMember_zSqqz3gw734c" title="Debt instrument repayment rate">1</span>% of the Event of Default Redemption Price for each 30 day period during which redemptions fail to be made. No event of default has occurred through September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">In addition, the Company granted Yozma a warrant to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrants to purchase common stock">16,956,929</span> ordinary shares for a period of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL9p1n7CJMX5" title="Warrants term">5</span> years with a fixed exercise price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrdbjxZIAK81" title="Exercise price of warrants">0.107415</span>, subject to certain adjustments (the “Warrant”). If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to Yozma, then the Warrant may also be exercised, in whole or in part, at such time by means of a net shares settlement. Moreover, Yozma is entitled to an option to require the Company to purchase the Warrant for cash in an amount equal to their Black-Scholes Option Pricing Model value (the Black-Scholes Model), upon occurrence of fundamental transactions, as defined in the warrant agreement, occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the management by assistance of third-party appraiser allocated the net cash proceeds received based on the relative fair value of the Note and the detachable warrants in total amount of $<span id="xdx_90C_eus-gaap--LoansPayableFairValueDisclosure_c20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pn3n3" title="Fair value of loans payable">423</span> and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pn3n3" title="Fair value of warrants">861</span>, respectively. The amount allocated to the warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price), net of any related issuance costs and as upon fundamental transaction the warrants holder shall be entitled to receive from the Company the same type of form of consideration such as holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore, it was determined that the embedded conversion feature is required to be bifurcated from the host loan instrument. The embedded conversion feature was recognized in total amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210101__20210122__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pn3n3" title="Beneficial conversion feature">2,116</span> upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The remaining amounted to $<span id="xdx_906_ecustom--RemainingAmountAllocatedForHostLoanInstrument_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_pn3n3" title="Remaining amount allocated for host loan instrument">423</span> was allocated to the host loan instrument, which in subsequent periods it is accounted for using the effective interest method over the term of the loan, until its stated maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded an income of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_pn3n3">1,666 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and expense of $<span id="xdx_90E_ecustom--RemeasurementExpense_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_pn3n3">742 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to remeasurement of the embedded conversion feature of convertible bridge loan and the discount amortization of the host loan instrument, respectively, as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine months ended September 30, 2021. During the period of three months ended September 30, 2021, the Company recorded Finance Expenses of $<span id="xdx_901_ecustom--FinanceExpense_pn3n3_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_znEYjCKGPeo6" title="Finance expense">164</span> and income of $<span id="xdx_90E_ecustom--FinanceIncome_pn3n3_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_zrsGcxNtOm47" title="Finance income">58</span> related to remeasurement of the embedded conversion feature of convertible bridge loan and the discount amortization of the host loan instrument, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">In addition, on October 7, 2020, the Company entered into consulting agreement with Aslano Private Limited (“Aslano”) whereby Aslano will render non-exclusive advice and service to the Company concerning equity and/or debt financing with certain Potential Buyer or Investor or Financing Party as defined in the consulting agreement in exchange for success fee equal to <span id="xdx_908_ecustom--SuccessFeePercentage_iI_pid_dp_c20210930__dei--LegalEntityAxis__custom--AslanoPrivateLimitedMember_zGS5lsmAChf6" title="Success fee percentage">8</span>% of the gross amount paid by the Potential Buyer or Investor or Financing Party. In consideration for Aslano’s non-exclusive services with respect to the aforesaid Securities Purchase Agreement, during the period of nine months ended September 30, 2021, the Company incurred incremental and direct finder fee cost of $<span id="xdx_90B_eus-gaap--ProceedsFromLoans_pn3n3_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEVCxCInKQg5" title="Proceeds from loans">272</span> which was allocated to the identified components (i.e. convertible bridge loans, bifurcated embedded conversion feature and detachable Warrant) consistent with the allocation of the proceeds issuance expenses. Consequently, an amount of $<span id="xdx_90B_ecustom--AdditionalDiscountOfConvertibleBridgeLoans_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_pn3n3" title="Additional discount of the convertible bridge loans">34</span>, $<span id="xdx_907_ecustom--ImmediateChargeToFinanceExpenses_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_pn3n3" title="Immediate charge to finance expenses">169</span> and $<span id="xdx_907_ecustom--DeductionOfAdditionalPaidinCapital_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_pn3n3" title="Deduction of additional paid-in capital">69</span> out of which was recorded as additional discount of the convertible bridge loans, immediate charge to finance expenses and as deduction of additional paid-in capital, respectively, at the outset of the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">For more information in connection to additional funds raising and filing of registration statement on Form S-1 under the aforesaid Securities Purchase Agreement subsequent to the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3 - SIGNIFICANT TRANSACTIONS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>First Amendment to Secured Convertible Equipment Loan Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">In March 2021, the Company entered into First Amendment to Secured Convertible Equipment Loan Agreement (the “Amendment”) with one of its lenders, under which the parties agreed (i) on or before May 1, 2021, the Company shall repay to the lender the Aggregate Loan Principal Amount of $<span id="xdx_90D_eus-gaap--RepaymentsOfDebt_c20210428__20210501__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember__srt--TitleOfIndividualAxis__custom--LenderMember_pn3n3" title="Repayments of debt">450</span> in cash, without interest, (ii) on or before May 1, 2021, the Company shall repay to the lender, or contribute to a charity designated by the lender, the original initial discount in the amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_c20210501__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember__srt--TitleOfIndividualAxis__custom--LenderMember_pn3n3" title="Original issue discount on loan">320</span>, plus an additional $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20210428__20210501__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember__srt--TitleOfIndividualAxis__custom--LenderMember_pn3n3" title="Officer compensation">100</span> as compensation for the lender agreeing to postpone repayment of the Aggregate Principal Amount and (iii) upon the execution of the Amendment, the Company shall issue to the lender, or contribute to a charity designated by the lender, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember__srt--TitleOfIndividualAxis__custom--LenderMember_z5TbyDjQkxf5" title="Stock issued during period shares restricted stock">2,000,000</span> restricted ordinary shares of the Company, nominal value NIS <span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210930__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--NISMember_z8lXgkTHQBxg" title="Shares issued, price per share">0.0001</span> per share with fair value of $<span id="xdx_903_eus-gaap--DerivativeFairValueOfDerivativeLiability_c20210930__us-gaap--TypeOfArrangementAxis__custom--ClosingAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_pn3n3" title="Investment">88</span>, as additional compensation to the lender for its agreement to defer repayment of the Aggregate Loan Principal Amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The management has determined mainly based on the qualitative terms of the amendment that the terms of the amended instruments considered as substantially different. Consequently, the original convertible bridge loans were derecognized, the new loans were initially recorded at fair value as current financial liability and the shares were initially recorded at fair value as an increase of additional paid-in capital. As of September 30, 2021 the loan was repaid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>D.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Closing Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">On March 3, 2021, the Company and one of its lenders entered into a Closing Agreement (the “Closing Agreement”), under which the lender exercised its right to invest an additional $<span id="xdx_907_eus-gaap--Investments_c20210930__us-gaap--TypeOfArrangementAxis__custom--ClosingAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_pn3n3">884 </span></span><span style="font: 10pt Times New Roman, Times, Serif">into the Company in the form of July 2020 Convertible Notes (the “Tranche 2 Securities”). In addition, the Company covenanted and agreed to file a registration agreement with respect to the Tranche 2 Securities on or before the earlier to occur of (i) the date that the Company files a registration statement with respect to any other securities of the Company or (ii) April 1, 2021 (such date, the “Tranche 2 Filing Date”) and cause a registration statement to be declared effective under the Securities Act with respect to the Tranche 2 Securities on or before May 1, 2021. <span id="xdx_903_eus-gaap--LossContingencyDamagesSought_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--ClosingAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember">The Company acknowledges that failure to timely comply with the foregoing obligations will subject the Company to substantial liability under the Registration Agreement, including without limitation liquidated damages in the amount of $250, along with an amount of cash accruing each month equal to the value of 1% of the value of the Tranche 2 Securities</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, it was determined that the embedded conversion feature is required to be bifurcated from the host loan instrument. The management by assistance of third-party appraiser measured the embedded conversion feature in total amount of $<span id="xdx_90E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn3n3_c20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zL8dyxoKqgBl" title="Investment">1,127</span> upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The excess of the fair value of identified instruments over net proceeds upon initial recognition amounted to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210827__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pn3n3" title="Beneficial conversion feature">243</span> was recorded as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations. In subsequent periods, the host loan instrument is accounted for using the effective interest method over the term of the loan, until its stated maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded interest expenses amounting to $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_znxc763X6zte">2,750 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to valuation of the loan to fair value upon default event and income of $<span id="xdx_905_ecustom--RemeasurementExpense_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_pn3n3">34 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to remeasurement of the embedded conversion feature, which were recorded as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine months ended September 30, 2021. During the period of three months ended September 30, 2021, the Company recorded Finance Expenses of $<span id="xdx_90F_ecustom--FinanceExpense_pn3n3_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_zRDVoxPcJMNb" title="Finance expense">2,647</span> related to valuation of the loan to fair value upon default event and $<span id="xdx_90D_ecustom--RemeasurementExpense_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanMember_zUsaxYRfRtbi">0</span> related to remeasurement of the embedded conversion feature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>E.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Assignment of Receivable Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, Corona Diagnostics (the “Assignor”) entered into Assignment of Receivable Agreements with Ascendant Partners, LLC (the “Assignee”) under which the Assignor assigned to the Assignee all of its right, title and interest in portion of receivable related to invoices for certain purchase orders with a discount in a rate of 10%. The Assignor is obligated to repurchase the PO in the event that payment is not received by the Assignee within 60-days period from the singing of the Assignment of Receivable Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, the Assignor received an amount of $<span id="xdx_909_eus-gaap--ProceedsFromSaleOfLoansReceivable_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--AssignmentOfReceivableAgreementsMember_pn3n3" title="Proceeds from receivable">1,467</span> under the Assignment of Receivable Agreements and repaid $<span id="xdx_900_eus-gaap--PaymentsForProceedsFromLoansReceivable_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--AssignmentOfReceivableAgreementsMember_pn3n3" title="Repayment for receivable">1,117</span>. In addition, the Company incurred finance expenses with respect to the applicable discount Interest under the Assignment of Receivable Agreements amounted to $<span id="xdx_90B_ecustom--FinanceExpensesWithApplicableDiscountInterest_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--AssignmentOfReceivableAgreementsMember_pn3n3" title="Finance expenses with applicable discount interest">50</span>. As of September 30, 2021, an amount of $<span id="xdx_908_eus-gaap--PaymentsForLoans_pn3n3_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--AssignmentOfReceivableAgreementsMember_zI3ceO3hKdO" title="Repayment for loans">400</span> has not been repaid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3 - SIGNIFICANT TRANSACTIONS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>F.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities Purchase Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On April 9, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with a Family Office Investor (the “Family Office”) to which the Company has agreed to issue a promissory convertible note (the “Note”) to the Family Office in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_pn3n3" title="Debt instrument, face amount">4,286</span> for proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_pn3n3" title="Proceeds from issuance of note">3,000</span> (the “Transaction”). The closing occurred on April 12, 2021. The Note has a maturity date of one year from the date of issuance and pays interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_zBwAchPTESld" title="Debt instrument, interest rate">4</span>% per annum. The Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_pdd" title="Debt Instrument, Convertible, Conversion Price">0.0599</span> (the “Conversion Price). In addition, the Family Office received a warrant (the “Warrant”) to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Warrants to purchase common stock">16,000,000</span> shares of Common Stock (the “Warrant Shares”) of the Company with an exercise price equal to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPoVMIGESaQd" title="Exercise price of warrants">0.107415</span> per share. The Warrant is exercisable for a <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziYebIaNUIFj" title="Warrants term">5</span>-year period from the issuance date. Upon a listing of the Company’s common shares onto a national exchange, the Note will exchange into a class of Series A Preferred Shares in order to help improve the Company’s shareholder equity to meet the Nasdaq CM Initial Listing Standards.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Family Office shall have the option, exercisable at the Family Office’s sole discretion, on the date that is ninety (90) days following the date of effectiveness of a registration statement filed by the Company, to purchase a Second Note and the Second Warrant, for a principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--FamilyOfficeInvestorMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_pn3n3" title="Debt instrument, face amount">4,286</span> for a consideration of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_c20210407__20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--FamilyOfficeInvestorMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_pn3n3" title="Proceeds from issuance of note">3,000</span> and a Warrant to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--FamilyOfficeInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_pn3d" title="Warrants to purchase common stock">16,000,000</span> shares of Common Stock, with an exercise price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--FamilyOfficeInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z6qJro55pJg4" title="Exercise price of warrants">0.107415</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the management by assistance of third-party appraiser allocated the net cash proceeds received based on the relative fair value of the Note and the detachable warrants in total amount of $<span id="xdx_907_eus-gaap--ProceedsFromSaleOfNotesReceivable_c20210406__20210409__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pn3n3" title="Cash proceeds from notes receivable">1</span> and $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_c20210406__20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pn3n3" title="Proceeds from Warrant">508</span>, respectively. The amount allocated to the warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price), net of any related issuance costs and as upon fundamental transaction the warrants holder shall be entitled to receive from the Company the same type of form of consideration such as holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore, it was determined that the Convertible note is hybrid instrument embodies both an embedded derivative and a host contract and that the embedded conversion feature is required to be bifurcated from the host loan instrument using the with-and-without method. The embedded derivative was measured first at fair value, and the residual amount was allocated to the host contract. The embedded conversion feature was recognized in total amount of $<span id="xdx_906_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_c20210406__20210409_pn3n3" title="Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature">3,007</span> upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The host loan instrument is accounted for, in subsequent periods, using the effective interest method over the term of the loan, until its stated maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded an income of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_zg2BXhHgCJaa">2,166 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and expenses of $<span id="xdx_900_ecustom--RemeasurementExpense_pn3n3_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_zoLQwWtbZDJ7">55 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to remeasurement of the embedded conversion feature of convertible bridge loan and the discount amortization of the host loan instrument, respectively, as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine months ended September 30, 2021. During the period of three months ended September 30, 2021, the Company recorded Finance Expenses of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_zu6fAXagdQEc">143</span> and income of $<span id="xdx_907_ecustom--RemeasurementExpense_pn3n3_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FamilyOfficeInvestorMember_zqoCQCBdCyWe">49</span> related to remeasurement of the embedded conversion feature of convertible bridge loan and the discount amortization of the host loan instrument, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Further to the Securities Purchase Agreement described in Note 3B, on April 27, 2021, the Company entered into an additional Securities Purchase Agreement (the “SPA”) with Yozma to which the Company has agreed to issue a promissory convertible note (the “Note”) to Yozma in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_pn3n3" title="Debt instrument, face amount">4,714</span> for proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20210426__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_pn3n3" title="Proceeds from issuance of note">3,300</span> (the “Transaction”). The closing occurred on April 27, 2021. The Note has a maturity date of one year from the date of issuance and pays interest at a rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zBot5lX1Gus3" title="Debt instrument, interest rate">4</span>% per annum. The Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member_zyPp2cGx9lUd" title="Debt Instrument, Convertible, Conversion Price">0.0599</span> (the “Conversion Price). In addition, Yozma received a warrant (the “Warrant”) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbEuwgPpsjd1" title="Warrants to purchase common stock">16,458,196</span> shares of Common Stock (the “Warrant Shares”) of the Company with an exercise price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLFY7uWqLZCb" title="Exercise price of warrants">0.107415</span> per share. The Warrant is exercisable for a <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcvthYY565Ei" title="Warrants term">5</span>-year period from the issuance date. Upon a listing of the Company’s common shares onto a national exchange, the Note will exchange into a class of Series A Preferred Shares in order to help improve the Company’s shareholder equity to meet the Nasdaq CM Initial Listing Standards.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the management by assistance of third-party appraiser allocated the net cash proceeds received based on the relative fair value of the Note and the detachable warrants in total amount of $<span id="xdx_902_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_c20210426__20210427__srt--TitleOfIndividualAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK2Fsj2DGShg" title="Cash proceeds from notes receivable">378</span> and $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20210406__20210409__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--YozmaGlobalGenomicFund1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pn3n3" title="Proceeds from Warrant"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20210427__us-gaap--ClassOfWarrantOrRightAxis__custom--DetachableWarrantsMember_zag41uQKMXuk" title="Detachable warrant">2,922</span></span>, respectively. The amount allocated to the warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price), net of any related issuance costs and as upon fundamental transaction the warrants holder shall be entitled to receive from the Company the same type of form of consideration such as holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - SIGNIFICANT TRANSACTIONS (Cont.)</b></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded expenses in the amount of $<span id="xdx_90C_eus-gaap--OperatingExpenses_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__custom--FinanaceExpensesMember_zWSxExN3xrDk">753 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--OperatingExpenses_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__custom--FinanaceExpensesMember_z9ujugcgX3aj">538</span></span><span style="font: 10pt Times New Roman, Times, Serif"> related to remeasurement of the host loan instrument as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine months and three months ended September 30, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has agreed to file a registration statement on Form S-1 with the Securities and Exchange Commission registering for resale the Conversion Shares and the Warrant Shares (the “Registration Statement) under the above two transactions. Subsequent to the effective date of such registration statement, if the closing sale price of the Common Stock averages less than the then Conversion Price over a period of 10 consecutive trading days, the Conversion Price shall reset to such average price. If the 10-days volume weighted average price of the Common Stock continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">On May 13, 2021, the Company filed a registration statement on Form S-1 with respect to up to <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210512__20210513__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__custom--FirstAndSecondTranchesMember_pdd" title="Stock Issued During Period, Shares, New Issues">240,591,462</span> ordinary shares to be issued pursuant to Securities Purchase Agreement with Family Office and Yozma (first and second Tranches). As the Company complied with the registration statement filing requirements, as of September 30, 2021, no accrual has been recorded for liquidated damages since the amount to be paid was not probable and reasonably estimate under ASC 450 “Contingencies”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On July 7, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Purchaser”) pursuant to which the Company has agreed to issue a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zM5zjuZQ9QEg" title="Debt instrument, face amount">1,536</span> for proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20210706__20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zUytX1OioTqd" title="Proceeds from issuance of note">1,075</span> (the “Transaction”). The closing occurred on July 7, 2021 (the “Closing Date”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zbihb1qk4U4f" title="Debt instrument, interest rate">4</span>% per annum. The Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zTzSeSUDDnHh" title="Debt Instrument, Convertible, Conversion Price">0.0599</span> (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zb3kIAGa9kna" title="Warrants to purchase common stock">3,440,000</span> shares of Common Stock (the “Warrant Shares”) of the Company with an exercise price equal to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zlqCWdWIm7Y6" title="Exercise price of warrants">0.107415</span> per share. The Warrant is exercisable for <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_za1Rl8AsimFl" title="Warrants term">5</span> years from the date of issuance. From the Closing Date until 180 days thereafter, the Company shall be restricted from issuing or entering into any agreement to issue any shares of Common Stock, except under certain circumstances. This provision shall no longer be in effect if the closing sale price of the Common Stock exceeds $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zzaPqcyCTCS5" title="Sales price">0.10</span>. The Company intends to use the net proceeds for general corporate purposes.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has agreed to file a registration statement with the Securities and Exchange Commission registering for resale of the Conversion Shares and the Warrant Shares (the “Registration Statement). Subsequent to the effective date of such registration statement, if the closing sale price of the Common Stock averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10-day volume weighted average price of the Common Stock continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the management by assistance of third-party appraiser allocated the net cash proceeds received based on the relative fair value of the Note and the detachable warrants in total amount of $<span id="xdx_90F_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_c20210706__20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_z2N12B4676o6" title="Cash proceeds from notes receivable">697</span> and $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20210706__20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zZITTJzXvQJd" title="Proceeds from Warrant">121</span>, respectively. The amount allocated to the warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price), net of any related issuance costs and as upon fundamental transaction the warrants holder shall be entitled to receive from the Company the same type of form of consideration such as holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore, it was determined that the Convertible note is hybrid instrument embodies both an embedded derivative and a host contract and that the embedded conversion feature is required to be bifurcated from the host loan instrument using the with-and-without method. The embedded derivative was measured first at fair value, and the residual amount was allocated to the host contract. The embedded conversion feature was recognized in total amount of $<span id="xdx_901_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_pn3n3_c20210706__20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zoktceWcCFy9" title="Conversion feature">257</span> upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The host loan instrument is accounted for, in subsequent periods, using the effective interest method over the term of the loan, until its stated maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded an expense of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20210706__20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z39V6R8ryszd">81 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and an expense of $<span id="xdx_90B_ecustom--RemeasurementExpense_pn3n3_c20210706__20210707__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z21g5YsQPP89">148 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to remeasurement of the embedded conversion feature of convertible bridge loan and the discount amortization of the host loan instrument, respectively, as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - SIGNIFICANT TRANSACTIONS (Cont.)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>4.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On September 15, 2021, the Company completed the conditions precedent required to enter into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Purchaser”) pursuant to which the Company issued a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zYGJj9RX4JCd">2,857</span> for proceeds of $</span><span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20210922__20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zxgNutjGSOth" style="font: 10pt Times New Roman, Times, Serif">2,000 </span><span style="font: 10pt Times New Roman, Times, Serif">(the “Transaction”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zqcax6ajEDUd">4</span></span><span style="font: 10pt Times New Roman, Times, Serif">% per annum. The Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zoiwMNHhoy46">0.0599 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_z80eCkusJ1G9">11,924,636 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Common Stock (the “Warrant Shares”) of the Company with an exercise price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zxpREQmYSYOj">0.107415 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. The Warrant is exercisable for <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_z5H12E4gSEYj">5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years from the date of issuance. The Company intends to use the net proceeds from this Note to initiate Phase 2/3 trials for Tollovir™ COVID-19 patients, initiate digital marketing for its dietary supplement Tollovid®, increase sales &amp; marketing for Provista Diagnostics, and for general corporate purposes.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has agreed to file a registration statement with the Securities and Exchange Commission registering for resale the Conversion Shares and the Warrant Shares (the “Registration Statement). Subsequent to the effective date of the Registration Statement, if the closing sale price of the Common Stock averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10 day volume weighted average price of the Common Stock continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the management by assistance of third-party appraiser allocated the net cash proceeds received based on the relative fair value of the Note and the detachable warrants in total amount of $<span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_pn3n3_c20210922__20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_z4o4HinKfVAf" title="Cash proceeds from notes receivable">1,290</span> and $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20210922__20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_z5YPc6cHb9v7" title="Proceeds from Warrant">558</span>, respectively. The amount allocated to the warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price), net of any related issuance costs and as upon fundamental transaction the warrants holder shall be entitled to receive from the Company the same type of form of consideration such as holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore, it was determined that the Convertible note is hybrid instrument embodies both an embedded derivative and a host contract and that the embedded conversion feature is required to be bifurcated from the host loan instrument using the with-and-without method. The embedded derivative was measured first at fair value, and the residual amount was allocated to the host contract. The embedded conversion feature was recognized in total amount of $<span id="xdx_906_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_pn3n3_c20210922__20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoeryConvertibleNoteMember_zstymPmIE6aj" title="Conversion feature">152</span> upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The host loan instrument is accounted for, in subsequent periods, using the effective interest method over the term of the loan, until its stated maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded an income of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20210922__20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zu6mjP6BMvNi" title="Beneficial conversion feature">3</span> and expenses of $<span id="xdx_905_ecustom--RemeasurementExpense_pn3n3_c20210922__20210923__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z53pZZdiZzr6" title="Remeasurement expense">45</span> related to remeasurement of the embedded conversion feature of convertible bridge loan and the discount amortization of the host loan instrument, respectively, as part of the “Finance Expenses” line in operations in the accompanying consolidated statement of operations for the period of nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>G.</b></span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>Secured Promissory Note</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On July 19, 2021, the Company entered into Secured Promissory Note (the “Note”) with a lender (the “Lender”), pursuant to which the Company has agreed to issue a Note to the Lender in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210719_zID1BDdFs5Yi" title="Debt principle amount">1,666</span> for proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20210718__20210719_zDrWgDOP2IY1">1,000</span> (the “Transaction”). The Note has a maturity date of 180 days from the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt"><b>H.</b></span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>Lease Agreement</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company signed a lease agreement for office space in Georgia, US through June 30, 2023 with monthly payments of $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_c20210101__20210930_zlIU8u0CbYNl" title="Lease expenses">104</span>.42. A lease liability in the amount of 182.19 and right-of-use asset in the amount of $182.19 have been recognized in the balance sheet as at September 30, 2021 in respect of the lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 450000 0.40 300000 750000 54000 0.125 2414000 2207000 81736111 750000 4857000 0.30 1457000 0.04 2022-01-22 0.07161 10 0.20 0.33 1.15 0.18 250000 0.01 16956929 P5Y 0.107415 423000 861000 2116000 423000 1666000 742000 164000 58000 0.08 272000 34000 169000 69000 450000 320000 100000 2000000 0.0001 88000 884000 The Company acknowledges that failure to timely comply with the foregoing obligations will subject the Company to substantial liability under the Registration Agreement, including without limitation liquidated damages in the amount of $250, along with an amount of cash accruing each month equal to the value of 1% of the value of the Tranche 2 Securities 1127000 243000 2750000 34000 2647000 0 1467000 1117000 50000 400000 4286000 3000000 0.04 0.0599 16000000 0.107415 P5Y 4286000 3000000 16000000 0.107415 1000 508000 3007000 2166000 55000 143000 49000 4714000 3300000 0.04 0.0599 16458196 0.107415 P5Y 378000 2922000 2922000 753 538 240591462 1536000 1075000 0.04 0.0599 3440000 0.107415 P5Y 0.10 697000 121000 257000 81000 148000 2857000 2000000 0.04 0.0599 11924636 0.107415 P5Y 1290000 558000 152000 3000 45000 1666000 1000000 104 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDCiHFZ4ceV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4 - <span id="xdx_82F_zqfnMbrM1fkh">SHAREHOLDERS’ DEFICIT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Ordinary Shares:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Ordinary Shares confer upon the holders thereof all rights accruing to a shareholder of the Company, as provided in these Articles, including, inter alia, the right to receive notices of, and to attend meetings of shareholders; for each share held, the right to one vote at all meetings of shareholders; and to share equally, on a per share basis, in such dividend and other distributions to shareholders of the Company as may be declared by the Board of Directors in accordance with these Articles and the Companies Law, and upon liquidation or dissolution of the Company, in the distribution of assets of the Company legally available for distribution to shareholders in accordance with the terms of applicable law and these Articles. All Ordinary Shares rank pari passu in all respects with each other.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>On July 26, 2021 the Annual General Meeting of the Company approved:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The resolution to amend the Company’s Articles of Association: (a) to authorize the creation of <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210726__us-gaap--StatementClassOfStockAxis__custom--RedeemablePreferredSharesMember_z1EX71ty0Qk6" title="Preferred stock, shares authorized">50,000</span> redeemable Preferred shares of the Company; (b) to authorize the creation of five thousand redeemable Preferred B Shares of the Company; (c) to increase the Company’s authorized share capital to permit the issuance of a total of up to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210726_zR9WtkKaTHfb" title="Preferred stock, shares authorized">5,000,000,000</span> ordinary shares of the Company; and (d) to allow the Company to fulfill relevant provisions of U.S. law in lieu of Israeli law requirements regarding External Directors, if and to the extent allowed to do so under Israeli corporate law and regulation was approved by the stockholders by the votes set forth in the table below</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The nomination of additional two external directors to the board of directors of the Company for a period ending on July 26, 2024.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The extension for an additional year the authority granted to the Company’s Board of Directors to effect a reverse split of the Company’s ordinary shares (as per resolution of the Company’s Shareholders’ Meeting of May 11, 2020), such that the authority so granted shall extend until July 26, 2022, and to expand such authority to include <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20210725__20210726_zEipGo030Gyl" title="Reverse stock split description">a reverse split of the Company’s entire share capital share at a ratio within the range from 1-for-2 up to 1-for 500, provided that the Company shall not effect reverse share splits that, in the aggregate, exceed 1-for-500</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Issuance of Ordinary Shares:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In March 2020, the Company entered into subscription agreements with several investors under which the Company raised gross funds in total amount of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200301__20200331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pn3n3" title="Number of ordinary shares issued, value">30</span> in exchange for the issuance of units consisting of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200301__20200331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zMvBtU9zD4d8" title="Stock issued during the period, shares">1,500,000</span> ordinary shares of the Company and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20200331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zA757jlfDnxg" title="Warrants exercised">1,339,284</span> warrants to purchase the same number of ordinary shares of the Company at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z0k2hYSNxUQ9" title="Exercise price of warrants">0.10</span>. These warrants may be eligible for exercise over a period of four years from the issuance date and are subject to standard anti-dilution provisions. In addition, the Company may be subject to liquidated damages upon failure to timely deliver shares upon exercise of the warrants. An amount of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zch1QsrJFkxf" title="Stock issued during the period, shares">1,000,000</span> and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zR4HMVGJS4P3" title="Stock issued during the period, shares">500,000</span> ordinary shares of NIS <span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zNiJ4DzPp6sh" title="Ordinary shares, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z61OqvhsUfR7" title="Ordinary shares, par value">0.01</span></span> par value out of the above have been issued during the year ended December 31, 2020 and the period of three months ended March 31, 2021, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On August 4, 2020, the Company entered into a Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has agreed to purchase from the Company, from time to time, up to $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pn3n3" title="Number of ordinary shares issued, value">10,275</span> of its ordinary shares, par value NIS <span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20200804__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z1bN0bsq5ODe" title="Ordinary shares, par value">0.01</span> per share (the “Ordinary Shares”), subject to certain limitations as set in the Purchase Agreement, during the Purchase Agreement term (the “Equity Line”).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company does not have the right to commence any further sales to Lincoln Park under the Purchase Agreement until all of the conditions thereto that are set forth in the Purchase Agreement, all of which are outside of Lincoln Park’s control, have been satisfied, including, among other things, the Registration Statement being declared effective by the SEC (the date on which all such conditions are satisfied, the “Commencement Date”). <span id="xdx_904_ecustom--ShareHolderDeficitDescription_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Share holder deficit, description">From and after the Commencement Date, under the Purchase Agreement, on any business day selected by the Company on which the closing sale price of the Company’s Ordinary Shares exceeds $0.02, the Company may direct Lincoln Park to purchase up to 500,000 Ordinary Shares on the applicable purchase date (a “Regular Purchase”), which maximum number of shares may be increased to certain higher amounts up to a maximum of 1,000,000 Ordinary Shares, if the market price of our Ordinary Shares at the time of the Regular Purchase equals or exceeds $0.13 (such share and dollar amounts subject to proportionate adjustments for stock splits, recapitalizations and other similar transactions as set forth in the Purchase Agreement), provided that Lincoln Park’s purchase obligation under any single Regular Purchase shall not exceed $500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 - SHAREHOLDERS’ DEFICIT (Cont.)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareHolderDeficitDescription_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember_z9jwv0fR9LJ3" title="Share holder deficit, description">The purchase price of Ordinary Shares the Company may elect to sell to Lincoln Park under the Purchase Agreement in a Regular Purchase, if any, will be based on 95% of the lower of: (i) the lowest sale price on the purchase date for such Regular Purchase and (ii) the arithmetic average of the three lowest closing sale prices for an Ordinary Share during the 15 consecutive business days ending on the business day immediately preceding such purchase date for such Regular Purchase</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts of the Company’s Ordinary Shares in “accelerated purchases” and in “additional accelerated purchases” under the terms set forth in the Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the Purchase Agreement, the Company issued 5,812,500 Ordinary shares to Lincoln Park as a commitment fee of $<span id="xdx_904_ecustom--CommitmentFee_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pn3n3">482 </span></span><span style="font: 10pt Times New Roman, Times, Serif">which is recorded as prepaid expenses which are amortized in accordance with the Equity Line utilization. During the periods of three and nine months ended September 30, 2021, the Company recorded amortization expenses amounting to $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pn3n3">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pn3n3">12</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, as part of “Finance Expenses” line in operations in the accompanying consolidated statement of operations. As of September 30, 2021, the balance of those prepaid expenses was $<span id="xdx_906_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pn3n3">361</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2020 and the period of nine months ended September 30, 2021, the Company sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zyiFwkIPbDy2" title="Stock issued during the period, shares">32,747,579</span> and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z09Wd14u7REg" title="Stock issued during the period, shares">5,229,809</span> Ordinary Shares to Lincoln Park in an initial purchase out of the Investment Amount under the Purchase Agreement for a total purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pn3n3" title="Number of ordinary shares issued, value">2,339</span> and $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementOneMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z2VtnfJuvU6e" title="Number of ordinary shares issued, value">255</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, Principal Amount and unpaid Interest in total amount of $<span id="xdx_901_ecustom--PrincipalAmountAndUnpaidInterest_c20210930__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember_pn3n3" title="Principal amount and unpaid interest">4,423</span> have been converted into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember_zLlxJZmOs6R4" title="Conversion of debt, shares">427,964,317</span> ordinary shares. In addition, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember_zJK3v6VVamZa" title="Stock issued during the period, shares">2,000,000</span> ordinary shares of NIS <span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember__us-gaap--AwardTypeAxis__custom--NISMember_zJO4mKZmFMch" title="Ordinary shares, par value">0.01</span> par value as fulfillment of commitment related to loan received in 2020.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>4.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, one of the Company’s Secured Convertible Equipment Loan Agreement was entered into default scenario as result of lapse of the original maturity date, as defined. Consequently, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_z6L8yP3mNuY5" title="Stock issued during the period, shares">20,000,000</span> ordinary shares of NIS <span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember__us-gaap--AwardTypeAxis__custom--NISMember_pdd" title="Ordinary shares, par value">0.01</span> par value of the Company were issued as collateral shares for purpose of repayment of the principal amount. The issued shares have been valued at $<span id="xdx_908_ecustom--FairValueOfOrdinaryShares_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuredConvertibleEquipmentLoanAgreementMember_pn3n3" title="Fair value of ordinary shares">870</span> and was deducted from the fair value of the principal amount.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>5.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, the Company entered into several service agreements with certain service providers, whereby the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SeveralServiceAgreementsMember_zBmQDr7GFSla" title="Stock issued during the period, shares">14,921,053</span> ordinary share of NIS <span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930__us-gaap--TypeOfArrangementAxis__custom--SeveralServiceAgreementsMember__us-gaap--AwardTypeAxis__custom--NISMember_pdd" title="Ordinary shares, par value">0.01</span> par value or the Company is committed to issue fixed number of ordinary shares in exchange for services that have been rendered. Consequently, the Company recorded related stock-based compensation expense of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SeveralServiceAgreementsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_pn3n3" title="Stock-based compensation expense">44</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SeveralServiceAgreementsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Stock-based compensation expense">31</span> as part of “Sales and Marketing Expenses” and “General and Administrative Expenses” lines in operations in the accompanying consolidated statement of operations, respectively.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 50000 5000000000 a reverse split of the Company’s entire share capital share at a ratio within the range from 1-for-2 up to 1-for 500, provided that the Company shall not effect reverse share splits that, in the aggregate, exceed 1-for-500 30000 1500000 1339284 0.10 1000000 500000 0.01 0.01 10275000 0.01 From and after the Commencement Date, under the Purchase Agreement, on any business day selected by the Company on which the closing sale price of the Company’s Ordinary Shares exceeds $0.02, the Company may direct Lincoln Park to purchase up to 500,000 Ordinary Shares on the applicable purchase date (a “Regular Purchase”), which maximum number of shares may be increased to certain higher amounts up to a maximum of 1,000,000 Ordinary Shares, if the market price of our Ordinary Shares at the time of the Regular Purchase equals or exceeds $0.13 (such share and dollar amounts subject to proportionate adjustments for stock splits, recapitalizations and other similar transactions as set forth in the Purchase Agreement), provided that Lincoln Park’s purchase obligation under any single Regular Purchase shall not exceed $500 The purchase price of Ordinary Shares the Company may elect to sell to Lincoln Park under the Purchase Agreement in a Regular Purchase, if any, will be based on 95% of the lower of: (i) the lowest sale price on the purchase date for such Regular Purchase and (ii) the arithmetic average of the three lowest closing sale prices for an Ordinary Share during the 15 consecutive business days ending on the business day immediately preceding such purchase date for such Regular Purchase 482000 0 12000 361000 32747579 5229809 2339000 255000 4423000 427964317 2000000 0.01 20000000 0.01 870000 14921053 0.01 44000 31000 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z2bLmDDuqSod" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5 - <span id="xdx_82B_zmLmGzboXtFh">STOCK OPTIONS</span></b> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On January 11, 2016, the Company’s Board of Directors approved and adopted the Todos Medical Ltd. 2015 Israeli Share Option Plan (the “2015 Plan”), pursuant to which the Company’s Board of Directors may award stock options to purchase its ordinary shares to designated participants. Subject to the terms and conditions of the 2015 Plan, the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designate participants; (ii) the terms and provisions of the respective Option Agreements, including, but not limited to, the number of Options to be granted to each Optionee, the number of Shares to be covered by each Option, provisions concerning the time and the extent to which the Options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the Fair Market Value of the Shares covered by each Option; (iv) make an election as to the type of Approved 102 Option under Israeli IRS law; (v) designate the type of Options; (vi) take any measures, and to take actions, as deemed necessary or advisable for the administration and implementation of the 2015 Plan; (vii) interpret the provisions of the 2015 Plan and to amend from time to time the terms of the 2015 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The 2015 Plan permits grant of up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20160110__20160111__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIsraeliShareOptionPlanMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of Options, Granted">6,000,000</span> options to purchase ordinary shares subject to adjustments set in the 2015 Plan. As of September 30, 2021, there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210930_pdd" title="Ordinary shares available for future issuance">2,338,838</span> ordinary shares available for future issuance under the 2015 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5 - STOCK OPTIONS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zxmTypWGRq4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table presents the Company’s stock option activity for employees and directors of the Company during the periods of three and nine months ended September 30, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B8_z6U84h8XScLk" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of July 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930_zVr1EGnrvpz5" style="width: 16%; text-align: right" title="Number of Options, Outstanding Beginning">2,545,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210701__20210930_zKVq6kCnInfd" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">0.095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930_pdd" style="text-align: right" title="Number of Options, Granted">13,750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210701__20210930_zLt9Sw7lw0h5" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930_zzsfxKlG2zy6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl1436">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210701__20210930_zzvdtFOC6yN4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">  <span style="-sec-ix-hidden: xdx2ixbrl1438"> </span>-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930_zbM6P2N0f091" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending">16,295,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210701__20210930_z0EZ5dE3u0H5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">0.040</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210701__20210930_zJuX3sRGXGR3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending">509,017</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210701__20210930_zyQwdvTA9PL7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">0.095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_z36HsftKdBCh" style="width: 16%; text-align: right">3,682,818</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930_z5SnqLZQNC7a" style="width: 16%; text-align: right">0.066</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_pdd" style="text-align: right" title="Number of Options, Granted">13,750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_znrMMgu3Jf38" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20210930_z0SEL1GCixFg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(1,137,735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z5YbsjioTGX" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">0.003</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_zeUgvMnYLZ86" style="border-bottom: Black 2.5pt double; text-align: right">16,295,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930_zp4Jb442FdK3" style="border-bottom: Black 2.5pt double; text-align: right">0.040</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of July 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20200930_zqkQvfZpmal2" style="width: 16%; text-align: right">2,267,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200701__20200930_zD3r0fhxtqf2" style="width: 16%; text-align: right">0.061</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.15in; padding-left: 0.15in">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20200930_pdd" style="text-align: right" title="Number of Options, Granted">2,545,083</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200701__20200930_zCfASe2q5Ho4" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.095</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.15in; padding-left: 0.15in">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200701__20200930_zQMNCVOzepUh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(1,129,836</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200701__20200930_zY6wZeUAzEJ2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">0.120</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200701__20200930_zxOMVovHgYcg" style="border-bottom: Black 2.5pt double; text-align: right">3,682,818</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200701__20200930_zRo1BN608OM4" style="border-bottom: Black 2.5pt double; text-align: right">0.066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.15in; padding-left: 0.15in">Exercisable as of September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20200701__20200930_zx2Avx6NkIe" style="border-bottom: Black 2.5pt double; text-align: right">1,137,735</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20200701__20200930_zvl47YQcm4qb" style="border-bottom: Black 2.5pt double; text-align: right">0.003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20200930_zcohnRt541k9" style="width: 16%; text-align: right">2,267,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20200930_zxLx7cU69Wbg" style="width: 16%; text-align: right">0.061</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.15in; padding-left: 0.15in">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930_pdd" style="text-align: right" title="Number of Options, Granted">2,545,083</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20200930_z539WJ4o958" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.095</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.15in; padding-left: 0.15in">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200101__20200930_zBTHzsUcSVS2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(1,129,836</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20200930_z5nspAN1gTyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">0.120</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of September 30, 2020</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200930_zKRYSKXu67ni" style="border-bottom: Black 1pt solid; text-align: right">3,682,818</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200101__20200930_zFXbDWsES147" style="border-bottom: Black 1pt solid; text-align: right">0.066</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zAfScNwiIIP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On July 29, 2020 (the “Commitment Date”), the Company held its Annual General Meeting of Shareholders, at which the shareholders of the Company approved compensation packages for two officers that include inter alia the Company is obligated to grant of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200726__20200729__srt--TitleOfIndividualAxis__custom--TwoOfficersMember_zyVOVXkbLXEd" title="Number of Options, Granted">2,545,083</span> stock options which are exercisable into the same number of shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20200729__srt--TitleOfIndividualAxis__custom--TwoOfficersMember_pdd" title="Exercise price of option">0.095</span> per share and shall become vested quarterly over a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20200726__20200729__srt--TitleOfIndividualAxis__custom--TwoOfficersMember_zBp7RG0j7h9i" title="Option vested period">5</span>-year period from its grant date. At the Commitment Date, the Company by assistance of third-party appraiser measured the fair value of the stock options in total amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200726__20200729__srt--TitleOfIndividualAxis__custom--TwoOfficersMember_zeDPW1Y3apLc" title="Fair value of stock options, value">206</span> by using Black-Scholes-Merton pricing model in which the assumptions that have been used are as follows: expected dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_c20200729__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z8UbTHgh0M4a" title="Measurement input">0</span>%; risk-free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_dp_uPure_c20200729__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zOcyVZFPkpMh">0.25</span>%; expected volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_dp_uPure_c20200729__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRateVolatilityMember_zlDq6Ghu0apa">131.9</span>%, and stock options exercise period based upon the stated terms.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In addition, as one-time bonus as compensation for uncompensated efforts to the Commitment Date, the Company is obligated to grant fully vested shares equal to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200726__20200729__srt--TitleOfIndividualAxis__custom--TwoOfficersMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Fair value of stock options, value">275</span> based on the fair market value of the Company’s shares as of July 28, 2020. The Company recorded stock-based compensation expense of this amount as part of “General and Administrative Expenses” line in operations in the accompanying consolidated statement of operations during the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Moreover, upon consummation of the Company’s planned public offering, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200726__20200729__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2050EWjvlMa" title="Number of shares issued">30,000,000</span> restricted stock units’ bonuses will be granted to the aforesaid officers. At the Commitment Date, December 31, 2020 and September 30, 2021, the likelihood that the Performance Milestone for consummation of the Company’s planned public offering was not considered as probable. Thus, during the year ended December 31, 2020 and the period of nine months ended September 30, 2021, stock-based compensation expense has not been recorded with respect to the Performance Milestone.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, the Company recorded stock-based compensation expense amounting to $<span><span id="xdx_902_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930__srt--TitleOfIndividualAxis__custom--TwoOfficersMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znKBqSThbSc2" title="Stock-based compensation expense">59</span>, as part of “General and Administrative Expenses” line in operations in the accompanying consolidated statement of operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On July 29, 2020 (the “Commitment Date”), the Company held its Annual General Meeting of Shareholders, at which the shareholders of the Company approved compensation packages for all its members of the Board of Directors that include inter alia grant of restricted stock units equal to aggregate amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ShareBasedCompensation_pn3n3_c20200726__20200729__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx0bvpr6Na19" title="Stock-based compensation expense">900</span> that shall become vested quarterly over a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20200726__20200729__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkOM9tM6l60e" title="Option vested period">3</span>-year period from its grant date (except the restricted stock of the board chairman who will be vested quarterly over a 1-year period).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the period of nine months ended September 30, 2021, the Company recorded stock-based compensation expense amounting to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z19GolIrZ8fe">350</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, as part of “General and Administrative Expenses” line in operations in the accompanying consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensation packages for officers and members of the Board of Directors and its committees</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On March 10, 2021, the Company’s Compensation Committee of the Board of Directors has approved compensation package for the Company’s Chief Executive Officer that include inter alia (i) based annual salary of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--OfficersCompensation_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zp39bw9eztRc" title="Annual salary">400</span>; (ii) an immediate granting of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_ecustom--GrantingPercentage_pid_dp_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2PHagOwaYqe" title="Granting Percentage">50</span>% of salary in restricted shares for uncompensated efforts to date; (iii) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--MilestoneBonusFeesDescription_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLwLYpDE7Yz5">up to 30% cash bonus based on predefined milestones or milestone bonuses in form of Restricted Stock Units ranging of 250,000 up to 2,000,000 common shares, and cash bonus range of $250 up to $1,500 which are based on cumulative volume of sales range from $25,000 up to $100,000 or milestone bonuses in form of Restricted Stock Units in value of $10,000 up to $50,000 which are based on market cap range of $1,000,000 up to $2,000,000 (“Milestone Bonus Fees”)</span>; (iv) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis__custom--OneTimeBonusMember_zvhSTdTLOf98" title="Bonus percentage">1.5</span>% of gross margin for the calendar year 2020 based on Board approval of the Company’s 2020 Financial Statements (“One-Time Bonus”); (v) grant of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3ZeXTcm8ZKh" title="Number of options, granted">8,750,000</span> stock options to purchase the same number of shares, vesting quarterly over the course of five years and (vi) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis__us-gaap--DeferredBonusMember_zcgjFsbQsPRj" title="Bonus percentage">50</span>% of base cash bonus and grant of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1AcJV2TAuy1" title="Number of Options, Granted">20,000,000</span> restricted shares upon consummation of the Company’s planned public offering (“Uplist Fees”).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE 5 - STOCK OPTIONS (Cont.)</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On March 10, 2021, the Company’s Compensation Committee of the Board of Directors has approved compensation package for the Company’s Chief Financial Officer that include inter alia (i) based annual salary of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--OfficersCompensation_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zCq16JCMpLNd">250</span></span><span style="font: 10pt Times New Roman, Times, Serif">; (ii) an immediate granting of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--GrantingPercentage_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zkbtw4WP6Znf">50</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of salary in restricted shares for uncompensated efforts to date; (iii) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_ecustom--MilestoneBonusFeesDescription_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zm39Hj4UATH3">up to 30% cash bonus predefined milestones or milestone bonuses in form of Restricted Stock Units range of 50,000 up to 200,000 and cash bonus range of $75 up to $300 which are based on cumulative volume of sales range of $25,000 up to $100,000 (“Milestone Bonus Fees”)</span></span><span style="font: 10pt Times New Roman, Times, Serif">; (iv) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis__custom--OneTimeBonusMember_zUbRUtOW6r92">0.5</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of gross margin for the calendar year 2020 based on Board approval of the Company’s 2020 Financial Statements (“One-Time Bonus”); (v) grant of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zxcyxdQ2DIBi">5,000,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">stock options to purchase the same number of shares, vesting quarterly over the course of five years and (vi) <span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_uPure_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis__us-gaap--DeferredBonusMember_zCrKdCM6oyz3" title="Granting percentage">50%</span> of base cash bonus and grant of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210309__20210310__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJq2nWJH1Uc3">10,000,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">restricted shares upon consummation of the Company’s planned public offering (“Uplist Fees”).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On March 10, 2021, the Company’s Compensation Committee of the Board of Directors has approved compensation package for the Company’s members of the Board of Directors and its committees that include inter alia (i) each board member will receive $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--OfficersCompensation_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--DirectorMember_zWtysXaLpsK7" title="Annual salary">65</span> annual salary (to be paid quarterly after financing) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--RestrictedStockExpense_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--DirectorMember_z1nMlCEOY0cb">150</span> in RSU vesting quarterly over three years; (ii) the Chairman of the board will receive $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--OfficersCompensation_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zPkdr88VRTRe" title="Annual salary">65</span> annual salary (to be paid quarterly after consummation of the Company’s planned public offering) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--RestrictedStockExpense_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z901vF9BkVT2">150</span> in RSU annually; (iii) Lead Independent Director is entitled to receive additional 100% of annual board cash compensation and RSU; (iv) a grant of RSU of the Company upon consummation of the Company’s planned public offering in an amount equal to annual compensation of each director (“Uplist Fee”) and (iv) cash bonus of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PaymentsToEmployees_pn3n3_c20210309__20210310__srt--TitleOfIndividualAxis__srt--DirectorMember_zNeUezVVfFwi" title="Cash bonus">71</span> to be paid for services of all board committees (“Bonus Fee”).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">On July 26, 2021 the Annual General Meeting of the Company approved the Compensation packages for officers and members of the Board of Directors and its committees as detailed above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the aggregate intrinsic value for the stock options outstanding and exercisable according to $<span id="xdx_90B_eus-gaap--SharePrice_c20210930_pdd">0.04 </span></span><span style="font: 10pt Times New Roman, Times, Serif">price per share is $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20210930_zgP7zA3nKjs">0</span></span><span style="font: 10pt Times New Roman, Times, Serif">, with a weighted average remaining contractual life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_z6RrWwg0N6qh">4.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation expenses incurred for employees (and directors) and non-employees for the period of nine months ended September 30, 2021, amounted to $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210930_zVdiLFfJmhIj" title="Share-based Payment Arrangement, Expense">558</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2021, the aggregate accrual for officers and members of the board and its committees in connection with salary and other benefits, amounted to $1,515 and is included in Other Current liabilities in the balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 6000000 2338838 <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zxmTypWGRq4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table presents the Company’s stock option activity for employees and directors of the Company during the periods of three and nine months ended September 30, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B8_z6U84h8XScLk" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of July 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930_zVr1EGnrvpz5" style="width: 16%; text-align: right" title="Number of Options, Outstanding Beginning">2,545,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210701__20210930_zKVq6kCnInfd" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">0.095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930_pdd" style="text-align: right" title="Number of Options, Granted">13,750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210701__20210930_zLt9Sw7lw0h5" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930_zzsfxKlG2zy6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl1436">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210701__20210930_zzvdtFOC6yN4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">  <span style="-sec-ix-hidden: xdx2ixbrl1438"> </span>-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930_zbM6P2N0f091" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending">16,295,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210701__20210930_z0EZ5dE3u0H5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">0.040</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210701__20210930_zJuX3sRGXGR3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending">509,017</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210701__20210930_zyQwdvTA9PL7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">0.095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_z36HsftKdBCh" style="width: 16%; text-align: right">3,682,818</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930_z5SnqLZQNC7a" style="width: 16%; text-align: right">0.066</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_pdd" style="text-align: right" title="Number of Options, Granted">13,750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_znrMMgu3Jf38" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20210930_z0SEL1GCixFg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(1,137,735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z5YbsjioTGX" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">0.003</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_zeUgvMnYLZ86" style="border-bottom: Black 2.5pt double; text-align: right">16,295,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930_zp4Jb442FdK3" style="border-bottom: Black 2.5pt double; text-align: right">0.040</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of July 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20200930_zqkQvfZpmal2" style="width: 16%; text-align: right">2,267,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200701__20200930_zD3r0fhxtqf2" style="width: 16%; text-align: right">0.061</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.15in; padding-left: 0.15in">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20200930_pdd" style="text-align: right" title="Number of Options, Granted">2,545,083</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200701__20200930_zCfASe2q5Ho4" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.095</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.15in; padding-left: 0.15in">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200701__20200930_zQMNCVOzepUh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(1,129,836</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200701__20200930_zY6wZeUAzEJ2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">0.120</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200701__20200930_zxOMVovHgYcg" style="border-bottom: Black 2.5pt double; text-align: right">3,682,818</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200701__20200930_zRo1BN608OM4" style="border-bottom: Black 2.5pt double; text-align: right">0.066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.15in; padding-left: 0.15in">Exercisable as of September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20200701__20200930_zx2Avx6NkIe" style="border-bottom: Black 2.5pt double; text-align: right">1,137,735</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20200701__20200930_zvl47YQcm4qb" style="border-bottom: Black 2.5pt double; text-align: right">0.003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20200930_zcohnRt541k9" style="width: 16%; text-align: right">2,267,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20200930_zxLx7cU69Wbg" style="width: 16%; text-align: right">0.061</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.15in; padding-left: 0.15in">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930_pdd" style="text-align: right" title="Number of Options, Granted">2,545,083</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20200930_z539WJ4o958" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.095</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.15in; padding-left: 0.15in">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200101__20200930_zBTHzsUcSVS2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(1,129,836</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20200930_z5nspAN1gTyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited or expired">0.120</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.15in; padding-left: 0.15in">Outstanding as of September 30, 2020</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200930_zKRYSKXu67ni" style="border-bottom: Black 1pt solid; text-align: right">3,682,818</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200101__20200930_zFXbDWsES147" style="border-bottom: Black 1pt solid; text-align: right">0.066</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 2545083000 0.095 13750000 0.030 16295083000 0.040 509017000 0.095 3682818000 0.066 13750000 0.030 1137735000 0.003 16295083000 0.040 2267571000 0.061 2545083 0.095 1129836000 0.120 3682818000 0.066 1137735000 0.003 2267571000 0.061 2545083 0.095 1129836000 0.120 3682818000 0.066 2545083 0.095 P5Y 206000 0 0.0025 1.319 275000 30000000 59000 900000 P3Y 350000 400000 0.50 up to 30% cash bonus based on predefined milestones or milestone bonuses in form of Restricted Stock Units ranging of 250,000 up to 2,000,000 common shares, and cash bonus range of $250 up to $1,500 which are based on cumulative volume of sales range from $25,000 up to $100,000 or milestone bonuses in form of Restricted Stock Units in value of $10,000 up to $50,000 which are based on market cap range of $1,000,000 up to $2,000,000 (“Milestone Bonus Fees”) 0.015 8750000 0.50 20000000 250000 50000 up to 30% cash bonus predefined milestones or milestone bonuses in form of Restricted Stock Units range of 50,000 up to 200,000 and cash bonus range of $75 up to $300 which are based on cumulative volume of sales range of $25,000 up to $100,000 (“Milestone Bonus Fees”) 0.005 5000000 0.50 10000000 65000 150000 65000 150000 71000 0.04 0 P4Y8M12D 558000 <p id="xdx_806_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTextBlock_zKqjazOiKv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6 - <span id="xdx_828_zc0209dyp7y4">FINANCING EXPENSES, NET</span></b></span></p> <p id="xdx_89D_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_zzft9Pae3s8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zGQ9eLhx3Uwc" style="display: none">SCHEDULE OF FINANCING EXPENSES </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_zAiO4x98FGO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF FINANCING EXPENSES (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20210101__20210930_zLKLCoWZwXmf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20200101__20200930_zOPXQbGngFyl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20210701__20210930_zfyY2y2vdvsl" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20200701__20200930_zXoCi4tqVlkj" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months period ended <br/>September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Unaudited</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Unaudited</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_ecustom--ModificationOfTermRelatingToStraightLoanTransaction_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Modification of terms relating to straight loan transaction</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1548">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInTermsRelatingToConvertibleBridgeLoansTransaction_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Modification of terms relating to convertible bridge loans transactions</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1552"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,495</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1554"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,334</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--LoansFromShareholdersExchangeRateDifferences_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exchange differences relating to loans from shareholders</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1557"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1559"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--IssuanceOfOrdinarySharesAndStockWarrantsUponModificationOfTermsRelatingToConvertibleBridgeLoanTransactions_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of ordinary shares and stock warrants upon modification of terms relating to convertible bridge loans transactions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IssuanceOfSharesAsSettlementInExcessOfTheCarryingAmountOfFinancialLiabilities_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of shares as a settlement in excess of the carrying amount of financial liabilities</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1567"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1569"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">734</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortization of discounts and accrued interest on convertible bridge loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,080</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,393</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,432</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AmortizationOfDiscountsAndAccruedInterestOnStraightLoans_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortization of discounts and accrued interest on straight loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1578"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1580"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueAdjustmentOfDerivativeLiability_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative warrants liability and fair value of warrants expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(299</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1583"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1585"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ChangeInFairValueOfLiabilityRelatedToConversionFeatureOfConvertibleBridgeLoans_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of liability related to conversion feature of convertible bridge loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,777</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1588"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1590"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--IssuanceOfSharesAsCallOptionsToAcquirePotentialAcquiree_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of shares as call options to acquire potential acquire</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1592"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1594"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SettlementInCashOfPrepaymentObligationRelatedToConvertibleBridgeLoan_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Settlement in cash of prepayment obligation related to convertible bridge loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--InterestAndRelatedRoyaltiesUnderReceivablesFinancingFacility_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest and related royalties under receivables financing facility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">546</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">633</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">633</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AmortizationOfPrepaidExpensesRelatedToCommitmentSharesInConnectionWithCreditLineAndEquityLine_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortization of prepaid expenses related to commitment shares in connection with receivables financing facility and equity line</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1610"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceIncomeCostsExchangeRateDifferences_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Exchange rate differences and other finance expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">250</td><td style="padding-bottom: 1pt; text-align: left"/><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,094</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(689</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">754</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FinancingIncomeExpensesNet_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Financing (income) expenses, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,360</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,055</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zMRC0Pufjghh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89D_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_zzft9Pae3s8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zGQ9eLhx3Uwc" style="display: none">SCHEDULE OF FINANCING EXPENSES </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_zAiO4x98FGO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF FINANCING EXPENSES (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20210101__20210930_zLKLCoWZwXmf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20200101__20200930_zOPXQbGngFyl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20210701__20210930_zfyY2y2vdvsl" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20200701__20200930_zXoCi4tqVlkj" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months period ended <br/>September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Unaudited</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Unaudited</b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_ecustom--ModificationOfTermRelatingToStraightLoanTransaction_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Modification of terms relating to straight loan transaction</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1548">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInTermsRelatingToConvertibleBridgeLoansTransaction_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Modification of terms relating to convertible bridge loans transactions</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1552"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,495</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1554"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,334</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--LoansFromShareholdersExchangeRateDifferences_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exchange differences relating to loans from shareholders</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1557"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1559"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--IssuanceOfOrdinarySharesAndStockWarrantsUponModificationOfTermsRelatingToConvertibleBridgeLoanTransactions_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of ordinary shares and stock warrants upon modification of terms relating to convertible bridge loans transactions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IssuanceOfSharesAsSettlementInExcessOfTheCarryingAmountOfFinancialLiabilities_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of shares as a settlement in excess of the carrying amount of financial liabilities</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1567"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1569"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">734</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortization of discounts and accrued interest on convertible bridge loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,080</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,393</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,432</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AmortizationOfDiscountsAndAccruedInterestOnStraightLoans_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortization of discounts and accrued interest on straight loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1578"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1580"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueAdjustmentOfDerivativeLiability_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative warrants liability and fair value of warrants expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(299</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1583"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1585"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ChangeInFairValueOfLiabilityRelatedToConversionFeatureOfConvertibleBridgeLoans_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of liability related to conversion feature of convertible bridge loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,777</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1588"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1590"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--IssuanceOfSharesAsCallOptionsToAcquirePotentialAcquiree_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of shares as call options to acquire potential acquire</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1592"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1594"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SettlementInCashOfPrepaymentObligationRelatedToConvertibleBridgeLoan_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Settlement in cash of prepayment obligation related to convertible bridge loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--InterestAndRelatedRoyaltiesUnderReceivablesFinancingFacility_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest and related royalties under receivables financing facility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">546</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">633</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">633</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AmortizationOfPrepaidExpensesRelatedToCommitmentSharesInConnectionWithCreditLineAndEquityLine_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortization of prepaid expenses related to commitment shares in connection with receivables financing facility and equity line</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1610"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceIncomeCostsExchangeRateDifferences_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Exchange rate differences and other finance expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">250</td><td style="padding-bottom: 1pt; text-align: left"/><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,094</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(689</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">754</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FinancingIncomeExpensesNet_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Financing (income) expenses, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,360</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,055</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 88000 -3495000 -7334000 40000 -43000 415000 415000 1234000 734000 18080000 8393000 4432000 10896000 2290000 1637000 -299000 -5000 -3777000 530000 3000000 1000000 182000 182000 546000 633000 495000 633000 293000 61000 293000 250000 1094000 -689000 754000 17360000 11375000 6875000 7055000 <p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zgdoqpqmopS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7 - <span id="xdx_826_z5llI3uvMgPh">TAXES ON INCOME</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">A.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred income taxes reflect the net tax effects of net operating loss and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows</span></td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z4MWWHaunm52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BE_ztNPaPuWnPvk" style="display: none">Schedule of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: justify"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20210930_zCO0jlYRyPl7" style="display: none; font-weight: bold; text-align: center">September 30,</td><td style="display: none; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><b>As of</b></p>September 30,</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Composition of deferred tax assets:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z4cWcpbOplxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: justify">Net operating loss carry-forward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">3,880</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_409_ecustom--DeferredTaxLiabilityInRespectOfSharePurchaseAgreement_iNI_pn3n3_di_zGYkIrJ43X0c" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><p style="margin: 0">Deferred tax liability in respect of Share Purchase Agreement (see note 1B)</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(315</td><td style="text-align: left">)</td> </tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iNI_pn3n3_di_ztSnvkOiOiO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,880</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_ztg78nn8gd24" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">(315</p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr> </table> <p id="xdx_8A2_zczQVLXRD1Mh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of September 30,2021 and December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">B.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the nine months ended September 30, 2021, the following table reconciles the statutory income tax rate to the effective income tax rate:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> </table> <p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ziFN2gB8GCB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zBxVeeZgKzH6" style="display: none">Schedule of Reconcile the Statutory Income Tax Rate to Effective Income Tax Rate </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: justify"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20210101__20210930_zm87KKeUockk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"><b>Unaudited</b></td><td> </td> </tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_zfAfqNCg8Y8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: justify; padding-bottom: 2.5pt">Tax rate</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right">23</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zCV2Kg25JF7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Tax expense (benefit) at statutory rate</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(5,647</td><td style="text-align: left">)</td> </tr> <tr id="xdx_40E_ecustom--IncomeTaxReconciliationTaxRateDifferential_zz5joyUm1Gmk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tax rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(31</td><td style="text-align: left">)</td> </tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_zqEbd1y9hFO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Permanent differences with respect to stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40A_ecustom--IncomeTaxReconciliationDerivativeWarrantsLiabilitiesBifurcatedConversionFeatureAndConvertibleLoans_zusXKMkqzhBc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Permanent differences with respect to derivative warrants liabilities, bifurcated conversion feature and convertible loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,815</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncreaseInTemporaryDifferences_zebD737Nes34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Change in temporary differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,733</td><td style="padding-bottom: 1pt; text-align: left"> </td> </tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zu4HSXz83577" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> <p id="xdx_8AF_zanU890U1ZV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left; text-indent: -63.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z4MWWHaunm52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BE_ztNPaPuWnPvk" style="display: none">Schedule of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: justify"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20210930_zCO0jlYRyPl7" style="display: none; font-weight: bold; text-align: center">September 30,</td><td style="display: none; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><b>As of</b></p>September 30,</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Composition of deferred tax assets:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z4cWcpbOplxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: justify">Net operating loss carry-forward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">3,880</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_409_ecustom--DeferredTaxLiabilityInRespectOfSharePurchaseAgreement_iNI_pn3n3_di_zGYkIrJ43X0c" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><p style="margin: 0">Deferred tax liability in respect of Share Purchase Agreement (see note 1B)</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(315</td><td style="text-align: left">)</td> </tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iNI_pn3n3_di_ztSnvkOiOiO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,880</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_ztg78nn8gd24" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">(315</p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr> </table> 3880000 315000 3880000 315000 <p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ziFN2gB8GCB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zBxVeeZgKzH6" style="display: none">Schedule of Reconcile the Statutory Income Tax Rate to Effective Income Tax Rate </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: justify"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20210101__20210930_zm87KKeUockk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"><b>Unaudited</b></td><td> </td> </tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_zfAfqNCg8Y8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: justify; padding-bottom: 2.5pt">Tax rate</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right">23</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zCV2Kg25JF7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Tax expense (benefit) at statutory rate</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(5,647</td><td style="text-align: left">)</td> </tr> <tr id="xdx_40E_ecustom--IncomeTaxReconciliationTaxRateDifferential_zz5joyUm1Gmk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tax rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(31</td><td style="text-align: left">)</td> </tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_zqEbd1y9hFO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Permanent differences with respect to stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40A_ecustom--IncomeTaxReconciliationDerivativeWarrantsLiabilitiesBifurcatedConversionFeatureAndConvertibleLoans_zusXKMkqzhBc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Permanent differences with respect to derivative warrants liabilities, bifurcated conversion feature and convertible loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,815</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncreaseInTemporaryDifferences_zebD737Nes34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Change in temporary differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,733</td><td style="padding-bottom: 1pt; text-align: left"> </td> </tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zu4HSXz83577" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> 0.23 -5647000 -31000 130000 3815000 1733000 <p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zmOx1m0q5Bh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8 – <span id="xdx_829_z32RaBOdAQUj">SEGMENT REPORTING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>General information</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Commencing 2020, the operations of the Company are conducted through three different core activities: Breast Cancer Test (TM-B1, TM-B2), Alzheimer and COVID-19 testing (commencing the fourth quarter of 2020), each of which are operating segments. These activities also represent the reportable segments of the Group.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The reportable segments are viewed and evaluated separately by Company management, since the marketing strategies, processes and expected long term financial performances of the segments are different.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Information about reported segment profit or loss and assets</b></span></td></tr> </table> <p id="xdx_89B_ecustom--ScheduleOfInformationAboutReportedSegmentProfitOrLossAndAssetsTableTextBlock_zrr3geTXwIKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BF_zWNobfWeG1T1" style="display: none">SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Breast</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">COVID-19</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cancer Test</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Alzheimer</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Testing</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Nine months ended September 30, 2021</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1pt">Revenues</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zF5GyIpvzyM3" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zbA1kugzmqBa" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zonE0omFZJcd" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues">7,773</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930_zXORa7GI9G44" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues">7,773</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Operating loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zAVE2hIQ93C7" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss">(4,685</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zobX4gFRBil5" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss"><span style="-sec-ix-hidden: xdx2ixbrl1664">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zJSizKvOShP6" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss">(996</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930_zItF5QW7gfE2" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss">(5,681</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify"><b>Unallocated amounts:</b></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Financing expenses, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--InvestmentIncomeNet_pn3n3_c20210101__20210930_zCpe4IwFeB91" style="border-bottom: Black 1pt solid; text-align: right" title="Financing expenses, net">(17,368</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Share in losses of affiliated companies accounted for under equity method, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">     </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--GainLossOnInvestments_pn3n3_c20210101__20210930_zSpUPMueQTda" style="border-bottom: Black 1pt solid; text-align: right" title="Share in losses of affiliated companies accounted for under equity method, net">(1,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: justify; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20210101__20210930_zFRz8qtLTA8i" style="border-bottom: Black 1pt solid; text-align: right" title="Net loss">(24,547</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><b>Total Assets</b></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Assets_iI_pn3n3_c20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zPAafvzUI3d9" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets">10,257</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zxiJIzPFJ2j3" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets"><span style="-sec-ix-hidden: xdx2ixbrl1678">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zF6py0ZkWxd9" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets">6,904</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--Assets_iI_pn3n3_c20210930_zJdAcIHHmaP1" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets">17,161</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify"><b>Other significant items:</b></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total expenditures for assets of reportable segment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zwJqFiPaqyJj" style="text-align: right" title="Total expenditures for assets of reportable segments">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zSaQI4hSRs2j" style="text-align: right" title="Total expenditures for assets of reportable segments"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zzEOEtEgmrb7" style="text-align: right" title="Total expenditures for assets of reportable segments">933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930_zzpclDgRsgje" style="text-align: right" title="Total expenditures for assets of reportable segments">935</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify">Total depreciation for reportable segment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zR67yp7vN1ig" style="text-align: right" title="Total depreciation for reportable segments">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zb9nwutQO1xa" style="text-align: right" title="Total depreciation for reportable segments"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zxw86MD4uTI8" style="text-align: right" title="Total depreciation for reportable segments">(504</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930_zHzdGoaOEAMl" style="text-align: right" title="Total depreciation for reportable segments">(526</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A2_zuqB4yGa44xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The evaluation of performance is based on the operating income of each of the three reportable segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounting policies of the segments are the same as those described in the accounting policies applied in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Due to the reportable segments’ nature, there have been no inter-segment sales or transfers during the reported periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financing expenses, net and the share of the Company in losses of affiliated companies were not allocated to the reportable segments, since these items are carried and evaluated on the enterprise level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management has determined that none of the equity method investees is eligible to be considered as reportable segment as they do not meet the criteria in ASC Topic 280-10-50 (or they did not commence their operations)..</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>C.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Revenues by geographic region are as follows:</b></span></td></tr> </table> <p id="xdx_895_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLRQVcLHRt7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BB_zGdYt7lCkAug" style="display: none">SUMMARY OF REVENUES BY GEOGRAPHIC REGION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td style="text-align: center"><b> </b></td> <td colspan="2" id="xdx_492_20210101__20210930_zky8TNcEP5Ua" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" id="xdx_490_20210701__20210930_zZ0TrVpt4BRi" style="font-weight: bold; text-align: center"><b>Three months <br/>period ended <br/>September 30,</b></td><td style="text-align: center; font-weight: bold"><b> </b></td><td style="text-align: center"><b> </b></td> <td colspan="2" id="xdx_493_20200101__20200930_zvLGGlRSWyfa" style="text-align: center"><b>Nine</b><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" id="xdx_49F_20200701__20200930_zQ12TZ8pz6f4" style="font-weight: bold; text-align: center"><b>Three months period ended September 30,</b></td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><b> </b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2020</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><b>2020</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IL_zJSBpaNNxCp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Israel</td><td> </td> <td style="text-align: right">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td> </td><td> </td> <td>$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td/><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td> </td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1705"> </span>-</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zkgbHVnFKbVh" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">United States</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">7,773</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,010</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,316</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,284</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zGl9OAawgsCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,773</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,010</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,284</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p id="xdx_8AF_zmROiWPWCyO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TODOS MEDICAL LTD.</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(U.S. dollars in thousands)</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 – SEGMENT REPORTING (Cont.)</b></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>D.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Property and equipment, net, by geographic areas:</b></span></td></tr> </table> <p id="xdx_89E_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_z7Xlu8CDJIbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BE_zCrOJ2PwxRVb" style="display: none">SUMMARY OF PROPERTY AND EQUIPMENT, NET, BY GEOGRAPHIC AREA</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20210930_zrtBuaxT5Y7c" style="font-weight: bold; text-align: center">As of </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20201231_zzWdBL3R9V7c" style="font-weight: bold; text-align: center">As of </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--IL_zeGDfSDwonb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">41</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--US_zLmo6dwK58oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">United States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,550</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,938</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zS9dH6RG4ytj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,591</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,999</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zxVGagDnnTOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>E.</b></span></td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Major customers</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three and nine months ended September 30, 2020, the Company had a major costumer representing 0% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJk7gtMFkOif">56.64% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the Company’s total sales. During the three and nine months ended September 30, 2021, the Company's revenues from the major costumer represented 0% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zlh94MHxx9ea">58.33% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the Company’s total sales. The Company’s contractual agreement to supply Covid-19 testing kits to the major customer has expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfInformationAboutReportedSegmentProfitOrLossAndAssetsTableTextBlock_zrr3geTXwIKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BF_zWNobfWeG1T1" style="display: none">SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Breast</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">COVID-19</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cancer Test</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Alzheimer</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Testing</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin: 0">Unaudited</p> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Nine months ended September 30, 2021</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1pt">Revenues</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zF5GyIpvzyM3" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zbA1kugzmqBa" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zonE0omFZJcd" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues">7,773</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210930_zXORa7GI9G44" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Revenues">7,773</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Operating loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zAVE2hIQ93C7" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss">(4,685</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zobX4gFRBil5" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss"><span style="-sec-ix-hidden: xdx2ixbrl1664">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zJSizKvOShP6" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss">(996</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingExpenses_pn3n3_c20210101__20210930_zItF5QW7gfE2" style="border-bottom: Black 1pt solid; text-align: right" title="Operating loss">(5,681</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify"><b>Unallocated amounts:</b></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Financing expenses, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--InvestmentIncomeNet_pn3n3_c20210101__20210930_zCpe4IwFeB91" style="border-bottom: Black 1pt solid; text-align: right" title="Financing expenses, net">(17,368</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Share in losses of affiliated companies accounted for under equity method, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">     </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--GainLossOnInvestments_pn3n3_c20210101__20210930_zSpUPMueQTda" style="border-bottom: Black 1pt solid; text-align: right" title="Share in losses of affiliated companies accounted for under equity method, net">(1,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: justify; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_c20210101__20210930_zFRz8qtLTA8i" style="border-bottom: Black 1pt solid; text-align: right" title="Net loss">(24,547</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><b>Total Assets</b></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Assets_iI_pn3n3_c20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zPAafvzUI3d9" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets">10,257</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zxiJIzPFJ2j3" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets"><span style="-sec-ix-hidden: xdx2ixbrl1678">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zF6py0ZkWxd9" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets">6,904</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--Assets_iI_pn3n3_c20210930_zJdAcIHHmaP1" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets">17,161</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify"><b>Other significant items:</b></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total expenditures for assets of reportable segment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zwJqFiPaqyJj" style="text-align: right" title="Total expenditures for assets of reportable segments">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zSaQI4hSRs2j" style="text-align: right" title="Total expenditures for assets of reportable segments"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zzEOEtEgmrb7" style="text-align: right" title="Total expenditures for assets of reportable segments">933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--TotalExpendituresForAssetsOfReportableSegments_pn3n3_c20210101__20210930_zzpclDgRsgje" style="text-align: right" title="Total expenditures for assets of reportable segments">935</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify">Total depreciation for reportable segment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--BreastCancerTestMember_zR67yp7vN1ig" style="text-align: right" title="Total depreciation for reportable segments">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--AlzheimerMember_zb9nwutQO1xa" style="text-align: right" title="Total depreciation for reportable segments"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930__us-gaap--StatementBusinessSegmentsAxis__custom--COVIDNineteenTestingMember_zxw86MD4uTI8" style="text-align: right" title="Total depreciation for reportable segments">(504</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--TotalDepreciationForReportableSegments_pn3n3_c20210101__20210930_zHzdGoaOEAMl" style="text-align: right" title="Total depreciation for reportable segments">(526</td><td style="text-align: left">)</td></tr> </table> 7773000 7773000 -4685000 -996000 -5681000 -17368000 -1499000 -24547000 10257000 6904000 17161000 2000 933000 935000 -22000 -504000 -526000 <p id="xdx_895_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLRQVcLHRt7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BB_zGdYt7lCkAug" style="display: none">SUMMARY OF REVENUES BY GEOGRAPHIC REGION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td style="text-align: center"><b> </b></td> <td colspan="2" id="xdx_492_20210101__20210930_zky8TNcEP5Ua" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" id="xdx_490_20210701__20210930_zZ0TrVpt4BRi" style="font-weight: bold; text-align: center"><b>Three months <br/>period ended <br/>September 30,</b></td><td style="text-align: center; font-weight: bold"><b> </b></td><td style="text-align: center"><b> </b></td> <td colspan="2" id="xdx_493_20200101__20200930_zvLGGlRSWyfa" style="text-align: center"><b>Nine</b><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" id="xdx_49F_20200701__20200930_zQ12TZ8pz6f4" style="font-weight: bold; text-align: center"><b>Three months period ended September 30,</b></td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><b> </b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2020</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><b>2020</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IL_zJSBpaNNxCp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Israel</td><td> </td> <td style="text-align: right">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td> </td><td> </td> <td>$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td/><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td> </td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1705"> </span>-</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zkgbHVnFKbVh" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">United States</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">7,773</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,010</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,316</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1,284</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zGl9OAawgsCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,773</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,010</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,284</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> 7773000 1010000 1316000 1284000 7773000 1010000 1316000 1284000 <p id="xdx_89E_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_z7Xlu8CDJIbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b><span id="xdx_8BE_zCrOJ2PwxRVb" style="display: none">SUMMARY OF PROPERTY AND EQUIPMENT, NET, BY GEOGRAPHIC AREA</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20210930_zrtBuaxT5Y7c" style="font-weight: bold; text-align: center">As of </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20201231_zzWdBL3R9V7c" style="font-weight: bold; text-align: center">As of </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--IL_zeGDfSDwonb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">41</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--US_zLmo6dwK58oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">United States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,550</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,938</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zS9dH6RG4ytj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,591</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,999</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 41000 61000 2550000 1938000 2591000 1999000 0.5664 0.5833 <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_z8wGVxgegzP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9 - <span id="xdx_82F_zeIdapuzfWD9">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were available to be issued (November 15, 2021). Based upon this review, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below<b>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">On October 21, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Purchaser”) pursuant to which the Company has agreed to issue a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp2p0_c20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember_zIF3VA6xZag6" title="Debt instrument, face amount">1,428,571.43</span> for proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20211020__20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember_zpMFGNRYQIS7" title="Proceeds from issuance of note">1,000,000</span> (the “Transaction”). The closing occurred on October 22, 2021 (the “Closing Date”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember_z5DyO17lFIgh" title="Debt instrument, interest rate">4</span>% per annum. The Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember_zBBB3sVr2gDa" title="Debt Instrument, Convertible, Conversion Price">0.0599</span> (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zX8Y2qRS0Ay9" title="Warrants to purchase common stock">3,440,000</span> shares of Common Stock (the “Warrant Shares”) of the Company with an exercise price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAidU29HcZhc" title="Exercise price of warrants">0.107415</span> per share. The Warrant is exercisable for <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211021__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZssGopbk7W5" title="Warrants term">5</span> years from the date of issuance. The Company intends to use the net proceeds from this Note to continue funding the ongoing Phase 2 clinical trial of Tollovir® in hospitalized COVID-19 patients, beginning the initial marketing campaign for the cPass neutralizing antibody test launch at Provista Diagnostics and general corporate purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has agreed to file a registration statement with the Securities and Exchange Commission registering for resale the Conversion Shares and the Warrant Shares (the “Registration Statement). Subsequent to the effective date of the Registration Statement, if the closing sale price of the Common Stock averages less than the then Conversion Price over a period of ten (<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uDays_c20211121__20211122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNOFxfjutxnc">10</span></span><span style="font-family: Times New Roman, Times, Serif">) </span>consecutive trading days, the Conversion Price shall reset to such average price. If the 10 day volume weighted average price of the Common Stock continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20211121__20211122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z6lKDJbdiqn4">20</span>% discount from the initial Conversion Price.</p> 1428571.43 1000000000 0.04 0.0599 3440000 0.107415 P5Y 10 0.20 The lower of (i) 0.05 (ii) the volume weighted average price (VWAP) of the last 20 trading days for the Ordinary Stock as reported in the OTC market prior to the conversion. The lower of (i) 0.05 (ii) the volume weighted average price (VWAP) of the last 20 trading days for the Ordinary Stock as reported in the OTC market prior to the conversion.